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ENGLISH SUMMARY
Venous thromboembolism (VTE) is a collective name for blood clots formed and lo-
cated in the deep veins of the body, and pulmonary embolism. Pulmonary embolism 
designates blood clots formed in the deep veins that detach from the breeding ground 
to flow with the venous blood and eventually settle in the arteries of the lungs. Even 
though VTE is a preventable disease, it remains a frequent complication that contribu-
tes considerably to morbidity and mortality in cancer patients. Prevention of VTE can 
be achieved by prophylactic anticoagulation treatment, however, prophylaxis is asso-
ciated with adverse events of which bleeding is the most substantial. Cancer patients 
are at higher risk of both VTE and bleeding than the background population. Thus, it 
is important to identify the subgroups of cancer patients with a particularly high risk 
of VTE and, furthermore, to narrow down their cancer-associated time interval with 
highest risk of VTE. In this way, prophylactic anticoagulation treatment can be offered 
in proper time to the cancer patients with highest benefit of prophylaxis.
This thesis is based on four epidemiological studies where associations between cancer 
specific factors and VTE were investigated in different groups of cancer patietns. Study 
1 showed that for some cancer types the degree of metastasis is associated with the risk 
of VTE in the sense that regional and/or distant metastasis increases the risk of VTE 
compared with localized disease, while for other cancer types the risk is high even in 
localized disease or conversely low regardless of stage. Study 3 showed that the risk of 
VTE in cancer patients who survive the acute effects of cancer, associated treatments 
and hospitalizations without VTE decrease to the level of the background population, 
except for patients with hematological cancer. Study 2 showed that especially my-
eloma patietns and chronic lymphocytic leukemia patients have a higher risk of VTE 
than the background population years after the diagnosis of hematological cancer. In 
study 4, the association between chronic lymphocytic leukemia and VTE was further 
investigated. Patients with chronic lymphocytic leukemia had a higher risk of VTE 
mostly because of additional cancer after the  diagnosis, but biological markers of the 
prognosis of chronic lymphocytic leukemia were also associated with the risk of VTE. 
In their entirety, the studies in this Ph.D. dissertation contributes to a more detailed 
understanding of when and which cancer patients are at highest risk of VTE. With 
other scientific contributions, the presented studies can aid in development of more 
personalized efforts against cancer-associated VTE in order to minimize premature, 
preventable death and morbidity in both patients with active cancer and those who 
survive the acute effects of cancer. 
DANSK RESUME
Venøs thromboemboli (VTE) er en samlebetegnelse for blodpropper dannet i krop-
pens dybe vener og lungeemboli, som betegner en blodprop dannet i kroppens vener, 
som har løsrevet sig fra arnestedet og sætter sig fast i lungernes arterier. VTE er en 
hyppig sygdom som bidrager betragteligt til dødelighed og reduceret livskvalitet 
hos cancerpatienter, også selvom blodfortyndende behandling kan forebygge VTE. 
Blodfortyndende behandling er forbundet med bivirkninger, hvoraf blødning er den 
væsentligste. Cancerpatienter har højere risiko for både blødninger og VTE end bag-
grundsbefolkningen, og det er derfor vigtigt at identificere de patienter, som er i sær-
lig høj risiko for at få VTE samt at finde ud af hvornår deres risiko er højest således 
at den forebyggende blodfortyndende behandling kan gives i de rigtige tidsinterval-
ler til de patienter som har mest gavn af det.
Denne afhandling bygger på fire epidemiologiske studier, hvor sammenhænge mel-
lem cancer specifikke faktorer og VTE er blevet belyst i forskellige grupper af cancer 
patienter. Studie 1 viste at graden af spredning (metastasering) i nogle cancer typer 
har betydning for risikoen for VTE forstået på den måde at regional spredning og/
eller fjern matestaser øger risikoen for VTE sammenlignet med lokal sygdom, mens 
graden af spredning for andre cancer typer ikke har nævneværdig betydning – enten 
fordi risikoen for VTE er høj ligegyldigt hvor meget canceren har spredt sig eller for-
di den er ditto lav. Studie 3 viste at risikoen for VTE hos patienter som overlever de 
akutte effekter af cancer, associerede behandlinger og indlæggelser uden VTE falder 
til baggrundsbefolkningens niveau, med undtagelse af de hæmatologiske cancer typer. 
Studie 2 viste at der blandt de hæmatologiske cancer typer var stor forskel på risikoen 
for VTE. Patienter med aggressive lymfomer, myelomatose og kronisk lymfatisk leu-
kæmi havde højere risiko for VTE end baggrundsbefolkningen. For de to sidstnævnte 
typer også mange år efter diagnosen af den hæmatologiske cancer. Studie 4 undersøg-
te forekomsten af VTE hos patietner med kronisk lymfatisk leukæmi mere detaljeret. 
Særligt patienter som fik diagnosticeret en cancer mere havde høj forekomst af VTE, 
men biologiske markører for dårlig prognose for kronisk lymfatisk leukæmi var også 
associeret med øget forekomst af VTE.
Alt i alt bidrager resultaterne omtalt i ph.d. afhandlingen til en mere nuanceret forstå-
else af hvornår hvilke cancer patienter er i højest risiko for VTE. Sammen med andre 
videnskabelige bidrag kan de danne grundlag for en mere skræddersyet forebyggende 
indsats mod VTE og dermed minimere forebyggelig forringelse af livskvalitet eller 
dødsfald både hos patienter med aktiv cancer og blandt dem som overlever de akutte 
effekter af cancer.
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INTRODUCTION
“It frightened the life out of me; I was more scared of that than the 
cancer. You know blood clots can kill you like that - cancer you’ve got 
a little bit of chance, you know.”
Quote from a Welsh cancer patient with venous thromboembolism.1
Venous thromboembolism (VTE) is a collective term for blood clots formed in the deep 
veins (i.e. deep vein thrombosis) and pulmonary embolism, where a blood clot formed 
in the deep veins dislodges to the arteries of the lungs. VTE secondary to cancer is 
prevalent and associated with serious personal and societal outcomes; for the indivi-
dual patient in forms of shortened life expectancy, physical and mental morbidity and 
prolonged hospitalization leading to increased health care costs for society.2-4 VTE is 
potentially preventable by use of thromboprophylactic medication, which is however, 
associated with a risk of bleeding. Cancer patients are prone to bleeding even without 
thromboprophylactic treatment, which is therefore optimally restricted to cancer pati-
etns with the highest risk of VTE in periods with some risk of VTE. The studies in this 
thesis investigated the etiology and epidemiology of cancer-associated VTE, which is 
important for future reduction of the mortality and morbidity caused hereby, by either 
aggressive thromboprophylaxis or modification of important risk factors. 
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BACKGROUND
 
VTE is among the most common cardiovascular diseases worldwide and is one of the 
leading causes of preventable in-hospital mortality and morbidity induced by adverse 
events in relation to hospitalization.5-9 Post thrombotic complications or recurrence of 
VTE impair the quality of life in 20 - 30% of VTE patients.10-14 Up to 50% of VTEs 
in the population occur under hospitalization or within the first three months after 
discharge.15,16 Underuse or insufficient dosing of thromboprophylaxis contributes to 
this even though VTE is a known preventable disease.17,18  Particularly medically ill 
hospitalized patients do not receive proper anticoagulation.19 A recent meta-analysis of 
11 randomized controlled trials showed that 21% more hospitalized patients received 
thromboprophylaxis and that the relative rate of VTE associated with hospitalization 
was decreased by 36% when medical health care professionals received alerts concer-
ning VTE risk.20 However, thromboprophylaxis comes at a price both in the literal, 
economic meaning and in terms of adverse medical events where bleeding represents 
the most common. 
Cancer patients have a higher risk of both bleeding and VTE than the cancer free 
subjects.21,22 The latter association was already described in French case reports 150 
years ago and is since repeatedly demonstrated in large population based studies.23-29 
International guidelines recommend thromboprophylaxis for cancer patients under-
going cancer surgery or elective surgery, hospitalized cancer patients admitted with 
an acute medical condition and high-risk ambulatory cancer patients including myelo-
ma patients treated with combinations of thalidomide.30-32 Only a few of these patient 
categories are well defined and considerations about thromboprophylactic therapy in 
cancer patients thus remain complex.  A recent Cochrane review concludes that pr-
ophylaxis with low molecular weight heparins reduced the relative risk of VTE by 46% 
compared with no administration of thromboprophylaxis in ambulatory cancer patients 
with even larger effect in ambulatory myeloma patients.33 On the other hand, a review 
and pooled analysis of three randomized trials concluded that the evidence to support 
thromboprophylaxis in hospitalized cancer patients is debatable.34
Several risk stratification models have been proposed to aid the clinical decision about 
thromboprophylaxis in cancer patients, but their external validity is not impressive.35 
This may have several explanations including lack of comparability in cancer popula-
tions, but moreover the impact of items included in the models change over time and 
more influential risk factors not included in the models may occur. These challenges 
for the risk assessment models appear increasingly relevant in the years to come, where 
accelerated cancer-diagnosing programs and successively improved cancer treatments 
increases the proportions of patients living with chronic cancer,36 even long enough to 
have second primary cancers.
This thesis is based on four studies that contributes to improved understanding of the 
impact of cancer stage, cancer type, time since cancer diagnosis and second primary 
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cancer on the risk of VTE. The following section outlines the epidemiology of VTE 
followed by a review of risk factors for VTE and the final section of this chapter sum-
marizes risk assessment models for cancer-associated VTE.
EPIDEMIOLOGY
VENOUS THROMBOEMBOLISM (VTE) IN THE GENERAL 
POPULATION
Overall, two circumstances draw estimates of the VTE burden in the population in 
opposite directions thereby challenging precise estimation. On the one hand, some 
VTEs are never diagnosed. Asymptomatic presentation of VTE or initial symptoms 
mimicking other diseases is common in VTE.37-39 The unspecific symptomatology can 
hinder the diagnosing of VTE.  Furthermore, fatal VTE events are underestimated due 
to low autopsy rates.7,40 On the other hand, the positive predictive value of VTE diag-
nosis codes used in register based studies is around 75%.41 This could lead to overe-
stimation of the VTE incidence in studies based on register data. Incidence rates (IR)
of VTE, however, ranges from 1.1 per 1000 person years (PY) to 1.8 per 1000 PY in 
large population based studies from the most recent years.6,14,42-44 
Several factors increase the risk of VTE, some of which are intrinsic to the patients 
(e.g. age and sex), while others are acquired (e.g. surgery, cancer). A VTE can be clas-
sified as provoked in case an acquired risk factor was present in temporal association 
with the VTE, whereas in cases with no obvious adequate acquired risk factor at the 
time of VTE, the event can be classified as unprovoked regardless of presence of in-
trinsic risk factors. Classification of a VTE event as either provoked or unprovoked is 
important, as it has implications for length of treatment and for the risk of recurrent 
VTE. For patients with VTE provoked by a transient risk factor (e.g. surgery), the an-
nual risk of recurrence is 3- 4%, while for VTE patients with unprovoked VTEs it is 
7-8%.45 In patients with VTEs provoked by a persistent, provoking factor (e.g. cancer), 
the 12-month recurrence risk is around 20%.21 Previous inconsistent definitions of pro-
voked/unprovoked VTE is one of the reasons why the proportion of unprovoked VTE 
ranges from 11% to 50% in earlier studies.6,14,46,47 The question whether a VTE was tr-
uly unprovoked is not revisited in large population based studies after the International 
Society of Thrombosis and Haemostasis (ISTH) Scientific Subcommittees of “Control 
of Anticoagulation and Predictive and Diagnostic Variables in Thrombotic Disease” 
proposed consistent categorization of VTE as provoked and unprovoked in a guideline 
from 2016.48 In an observational study of 331 patients with pulmonary embolism from 
2018, it was found that 67% of the events were provoked by acquired risk factors.49 
Hospitalization is a proxy for many of the intrinsic and acquired risk factors. In an 
epidemiological model, it was estimated that 762 000 symptomatic VTEs occur-
red in France, Germany, Italy, Spain, Sweden and the UK in 2004, and 63% of the-
se cases were related to hospitalization.7 A recent Australian study found an IR of 
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hospitalization associated VTE of 9.3 per 1000 hospital admissions. The majority was 
diagnosed within the first three months after the discharge date.50 VTE in association 
with hospitalization is prevalent in all parts of the world. In a study based on previously 
published data from both high and low-income countries, the annual IR of VTE was 
around 3 per 100 hospital admissions for both high-income and low-income countries.5 
VTE is one of the leading preventable causes of disability and premature death after 
hospitalization worldwide with 7.7 million lost disability-adjusted life-years, thereby 
surpassing both falls in the hospital, nosocomial infections, adverse drug events and 
decubitus ulcers.5 
Mortality and morbidity following VTE in the general population
VTE is a serious condition that increases mortality and morbidity in affected indivi-
duals. In the model based on data from six European countries, it was estimated that 
12% of all deaths is due to VTE.7 Population based studies have shown that 20 - 30 
% of patients with VTE die within the first year after VTE diagnosis.6,14,51 In a Danish 
nationwide follow-up study, it was shown that the 30-day mortality in subjects with 
VTE was 33-fold higher compared with age and gender matched controls.52 Mortality 
remains about 2-fold higher in subjects with VTE compared with reference subjects 
for as long as 30 years after a VTE diagnosis.52-54 
Morbidity after VTE is frequent in case of both deep vein thrombosis and pulmonary 
embolism. After a pulmonary embolism, more than one-third of the patients have at 
least mild functional impairment, both related to persistent right ventricular dysfuncti-
on and general deconditioning.55,56 Particularly dyspnea and reduced walking distance 
lowers the quality of life in survivors of pulmonary embolism.57Chronic thrombotic 
pulmonary hypertension is seen in 4 – 5% of patients who survive pulmonary embolism 
and these patients have severely reduced quality of life and high mortality. 10,58-61 After 
a deep vein thrombosis, up to 50% of patients are burdened by post thrombotic syndro-
me, which is a condition caused by chronic venous valve insufficiency and persistent 
obstruction in the deep veins after deep vein thrombosis.11,12,62-65 Pain, edema, venous 
ulcers and phlebitis in the affected leg and hereby-impaired daily activity lowers the 
quality of life in patients with severe post thrombotic syndrome to levels comparable 
to patients with congestive heart failure, cancer or angina.62
Besides the post thrombotic complications, patients with VTE are at risk of recurrent 
VTE, which probably further adds to morbidity and mortality. Most recurrences occur 
within the first year after initial VTE diagnosis. Incidence rates of recurrent VTE of 11 
per 100 PY were found in both the Tromsø study and in the UK.14,51 In both studies, 
the IR of recurrent VTE fell to around 2 per 100 PY after the first year.
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VTE IN CANCER PATIENTS
Around 20% of all VTEs occur in subjects with cancer at the time of VTE diagno-
sis.16,25,42,66,67 The risk of VTE is increased by 4-5 - fold in cancer patients compared 
with the general population and even more if restricted to periods with active can-
cer.24-27 Several studies have reported increasing proportions of VTE in cancer pa-
tients over the last 2-3 decades. Suggested explanations include increased awareness 
of VTE risk in cancer patients, better diagnostic tools, improved survival of cancer 
patients and use of more thrombogenic anti-cancer treatments to later stage patients 
over time.26,68-70  It is thus not evident that the observed increased incidence of VTE in 
cancer patients is not merely a result of under-diagnosing of VTE in the past. Offhand, 
reports of the incidence of VTE in cancer populations might seem a straightforward 
task. However, several factors influence the effect estimates. First, the markedly higher 
mortality of cancer patients compared with other subjects in the population can have 
a remarkable effect on the risk estimates. Second, the risk of VTE differs widely with 
time since cancer diagnosis and reported effect estimates are highly dependent of this. 
Furthermore, there are many different definitions of VTE and reasons for exclusion of 
events in existing literature.
These methodological aspects of estimating the VTE risk in cancer populations are 
elaborated below, followed by a review of the consequences of VTE in cancer patients. 
The competing risk of death and definition of VTE
Cancer patients have a higher mortality than the background population.71 In a mul-
tinational study based on population-based cancer registry data, the age-standardized 
1-year survival in breast cancer was between 88.6% and 97.6% while it was between 
23.0% and 41.7% for lung cancer patients.72 The considerable although variable mor-
tality in cancer populations constitutes a problem in time-to-event analysis where the 
assumption of non-informative censoring must not be violated.73 For the fulfillment 
of this assumption in studies of VTE in cancer populations, cancer patients who are 
censored in the analysis because of death would need to have the same risk of VTE as 
those still left for follow-up. Since this is unlikely (i.e. those who die would assumably 
have a higher risk of VTE than those still left in the study) it is necessary to take the 
competing risk of death into consideration when estimating the risk of VTE in cancer 
populations.74,75 Since this focus has just recently emerged, only a minor fraction of 
studies concerning VTE in cancer populations investigated the risk of VTE with met-
hods that allow for the competing risk of death (Table 1).24,27,75
The first prospective study that compared the risk of VTE in cancer patients with the 
background population treating death as competing risk, found a 1-year cumulative 
incidence of VTE of 1.4% in cancer patietns.24 This study by Cronin-Fenton et al. 
only included cases hospitalized for the VTE and excluded VTE diagnosed solely in 
emergency departments because of low predictive value.41 Moreover, a considerable 
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proportion of the cancer patients in the study had breast and prostate cancer, which 
are associated with lower mortality than other cancer types. Thus, the effect of trea-
ting death as competing risk and the definition of VTE events (leading to exclusion of 
events) both explain why the estimates do not differ markedly from previously publis-
hed studies not accounting for the competing risk of death (Table 1).28,68,76 However, 
the overall incidence rate of VTE was also lower in the study by Cronin-Fenton than 
in a study based on data from four registers in the UK by Walker et al.26 The resulting 
cohort encompassed 83 203 cancer patients followed from the date of cancer diagnosis 
for a median of 2 years reaching an overall IR of VTE of 13.9 per 1000 PY including 
non-hospitalized VTE cases, contrary to the study by Cronin-Fenton et al. In a cohort 
of prospectively followed patients with either a newly diagnosed cancer or progressi-
on of cancer after remission, Ay et al. found a 1-year cumulative incidence of VTE of 
7.6% treating death as competing risk, which is considerably higher than the cumu-
lative incidence reported by Cronin-Fenton et al. (Table 1).24,75  Presumably, some of 
the difference is caused by a broader definition of VTE and a much larger proportion 
of patients with brain tumors in the study by Ay et al. Brain tumors are consistently 
described as associated with very high risk of VTE with 1-year incidences of around 
20%, and more than 10-fold increased risk of VTE compared with the general popu-
lation.77-79 Hence, even minor differences in proportions of patients with brain tumors 
in studies concerning VTE may lead to considerable differences in observed absolute 
estimates of VTE risk. Furthermore, Ay et al. excluded patients with prostate cancer 
from the analysis because of few events in this group. However, burden of VTE in the 
total population is to some degree attributable to prostate cancer as this is one of the 
most frequent cancer types.27,80,81
Time since cancer diagnosis
Time since cancer diagnosis has a major influence on occurence and effect estimates. 
Studies consistently report that most cancer-associated VTEs occur within the first few 
months after cancer diagnosis.24-26,76 In a recent study by Cohen et al., the epidemiology 
of VTE in periods with active cancer in UK residents was investigated. Active cancer 
was defined as the 90 days preceding a hospital discharge diagnosis of primary cancer 
or cancer treatment encompassing bone marrow transplant, radiation or chemothera-
py during hospitalization plus the subsequent 90 days here after.25 The IR of VTE in 
periods with active cancer was 58 per 1000 PY. Walker et al. reported similar high 
IR of VTE during the first three months in the study (IR VTE 0-3 months after cancer 
diagnosis was 47 per 1000 PY).26 Blix et al. specifically investigated the impact of time 
since cancer diagnosis in a study based on data from the Scandinavian Thrombosis 
and Cancer (STAC) cohort.27 Cancer was treated as a time varying exposure, death 
was treated as competing risk and median follow-up was 2.3 years. The IR of VTE 
ranged from 2.9 per 1000 PY in the 12 - 6 months before cancer diagnosis to 31.4 per 
1000 PY within the first six months after the cancer diagnosis, IR fell with successive 
time since cancer diagnosis but remained higher than the 12-6 months before cancer 
diagnosis. Both hazard ratios (HR) and sub-distributional HRs (SHR) were calculated 
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in order to illuminate the importance of competing risk of death, which is particularly 
distinct in the first months after the cancer diagnosis.27 Incidence rates of VTE with 
increasing time since cancer diagnosis were similar to what Walker et al. reported: 
Around 30 per 1000 PY for the first 6 months after cancer diagnosis and about 8 per 
1000 PY >12 months after cancer diagnosis (Table 1).26 
Consequences of VTE in cancer patients
Mortality
Venous thromboembolism affects survival in general and particularly in cancer pa-
tients. Despite variation in study populations and designs, several studies report that 
mortality in cancer patients with VTE is about two fold higher than in VTE free cancer 
patients, however with some variation due to cancer type.2,29,67,76,82 Even asymptomatic 
deep vein thrombosis and superficial vein thrombosis were associated with a 2.4-fold 
increased risk of death in a prospective study where 150 VTE patients were follow-
ed for nine months in an outpatient clinic.83 Based on data from the Tromsø study,84 
Timp et al. calculated age and gender adjusted HRs of death in case of VTE, cancer 
only and cancer plus VTE compared with subjects neither exposed to cancer nor VTE. 
They found VTE alone was associated with a 2.6 - fold increased risk of death and 
subjects with cancer only had a 7.4 - fold higher risk of death, while those with both 
cancer and VTE had a 31.2 - fold higher risk of death compared with subjects free 
of VTE and cancer.85 Several studies of VTE in single types of cancer report higher 
mortality in case of VTE. For lung cancer patients, the risk of death was around 50% 
higher for those exposed to VTE in two large population based cohorts where VTE 
was included as a time varying exposure in the regression models.86,87 Large studies 
based on data from the US found higher mortality for cancer patients with local or re-
gional spread cancer and VTE compared with patients with same cancer stage and no 
VTE, whereas the impact of VTE on survival was weaker or even absent in patients 
with distant metastasis.87-90 
Recurrence of VTE
Recurrent VTE is more frequent among cancer patients than in cancer free subjects. 
In the RIETE study, 4.5% of cancer exposed subjects had recurrent VTE, while 1.4% 
had recurrent VTE in the cancer free subset of the population. The HR of recurrence 
for cancer patients with metastases compared with study subjects without cancer was 
5.6 (95% CI, 3.7-8.4), for cancer without metastases the HR was 2.6 (95% CI, 1.8-
3.8).67,91 Similar differences were observed in a single center, prospective cohort of 842 
patients with DVT. The 12-month cumulative incidence of recurrent VTE was 20.7% 
in patients with cancer, while the 12-month cumulative incidence of recurrence was 
6.8% in VTE patietns without cancer.21 Death was however not treated as competing 
risk in this study, which would tend to increase the difference in recurrence rates in 
the two groups, as the mortality is probably not similar in the two groups.92 In a study 
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based on data from a randomized clinical trial, Parpia et al. found a 180-day cumula-
tive incidence of recurrent VTE of 6-12% treating death as competing risk in cancer 
patients treated for VTE. The risk of recurrence was 2.7-fold higher in case of meta-
stasis compared with no metastasis.93 
The mortality of cancer patients is probably further increased in cases of recurrent VTE. 
In a cohort of Olmsted, US residents diagnosed with cancer-associated VTE between 
1966-2000, the 10-year cumulative incidence of recurrent VTE was 29% treating de-
ath as competing risk. Recurrent cases encompassed thrombus extension ≥ 24 hours 
after the initial VTE diagnosis (i.e. new or worsening symptoms of VTE).  Patients 
with active cancer had higher recurrence rates than those with previously active cancer, 
particularly lung, brain, ovarian cancer, advanced cancer stage or cancer stage pro-
gression and myeloproliferative and myelodysplastic syndromes were associated with 
increased risk of recurrent VTE. In a univariate Cox model including recurrent VTE as 
a time-dependent predictor, the HR of death was 2.9 (95% CI ,2.3-3.6) for those with 
recurrent VTE compared with those with no VTE recurrence. No confounders were 
however added to the model, possibly due to statistical power and study aims.94 In the 
study by Cohen and colleages,25 the overall incidence rate of recurrent VTE was 9.6 
per 100 PY (95% CI, 8.8-10.4), however markedly higher within the first six month 
after the initial VTE diagnosis in cancer patients (IR of recurrent VTE < 180 days was 
22.1 per 100 PY [95% CI, 19.9-24.4]). The 10-year cumulative incidences of recurrent 
VTE were lower than observed in the Olmsted cohort94, probably partly due to diffe-
rent definitions of recurrent VTE.
Side effects of antithrombotic treatment
Treatment for VTE is associated with adverse events of which bleeding is the most 
important. The risk of bleeding after anticoagulation treatment for VTE is higher in 
cancer patients than in cancer free VTE patients.21 The Hypertension, Abnormal renal/
liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, 
Drugs or alcohol use (HAS-BLED) score was developed to assess bleeding risk and net 
benefit of anticoagulation in patients with atrial fibrillation.95 Recently, the HAS-BLED 
score was validated in a US cohort of 132 280 VTE patients of whom 19% had cancer. 
In this population-based cohort, 3.6% of the patients experienced bleeding, and 39% of 
these were classified as major bleeds. The cumulative incidence of bleeding was hig-
her in cancer patients than in subjects without cancer, and cancer patients had a 2-fold 
increased risk of bleeding compared with non-cancer subjects.22 In the Hokusai VTE-
cancer study, 1050 patients with cancer-associated VTE was randomized to treatment 
with either a low molecular weight heparin or a non-vitamin K oral anticoagulant.96 
Major bleeding as defined by the ISTH97 was observed in 3-6 % of the patients during 
a median anticoagulation treatment period of 184 days.98 However, not only bleeding 
episodes defined as major are burdensome for the patients, and it is thus relevant to 
include non-major bleedings when assessing the risk of bleeding.99 Non-major bleeds 
were included in analysis of data from the CATCH trial where the efficacy and safety 
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of low molecular weight heparin and vitamin K antagonist treatment of acute VTE in 
patients with active cancer was investigated.100 In total, 15% of the study participants 
experienced clinically relevant bleeding episodes.101 
Psychological and physical consequences for the patients
The opening quote from the Welsh cancer patient with VTE is one of many in recent 
studies that have assessed the qualitative aspects of cancer-associated VTE. As clear-
ly stated, cancer patients with VTE experience psychological stress, not only in as-
sociation with symptoms of VTE, but also in the diagnostic process and treatment of 
VTE.1,3,102-105 Physical symptoms related to the VTE and related treatment also nega-
tively affect the quality of life of patients with cancer-associated VTE, but treatment 
does improve both the physical and mental health over time.105   
Health-economic consequences
The expenses for cancer patients with VTE are considerably higher compared with 
cancer patients without VTE. In a US study, 912 patients with VTE were matched on 
age and gender to 2736 cancer patients without VTE. After adjustment for cancer type, 
demographic factors and clinical confounders, VTE increased the economic cost by 
30%.4 The main contributor to this was longer duration of hospitalization due to com-
plications and recurrences, which is also observed in other studies.106-108 
In summary, the risk of VTE in cancer patients is considerable despite methodological 
challenges in estimating the precise burden of cancer-associated VTE in the population. 
It is evident that cancer patients with VTE have reduced survival compared with VTE 
free cancer patients, and that cancer patients exposed to VTE have a considerable risk 
of recurrent events despite treatment, which is associated with clinically relevant blee-
ding for a substantial proportion of the patients. Cancer-associated VTE is burdensome 
for both the health economy, and not least for the patients. A recent literature review 
concluded that the high incidence of VTE in cancer patients and subsequent economic 
and personal burden of cancer-associated VTE necessitate evidence based preventi-
on of VTE in cancer patients.109This prevention is already sought, but the etiology of 
VTE in cancer patients is complex. Prediction of the VTE risk in cancer patients is 
challenged by this fact and by influence from non-cancer related risk factors for VTE 
at a person level. General and cancer-associated risk factors for VTE are reviewed in 
the following section. 
RISK FACTORS FOR VENOUS THROMBOEMBOLISM
Several factors are related to the risk of VTE at person level. Some risk factors are 
intrinsic qualities of the patient (e.g. genetic risk factors, age, sex) while others are 
acquired, provoking factors (e.g. hospitalization, cancer, surgery). All factors that in-
fluence the risk of VTE do so by disturbing the balance between three causes known 
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as Virchow’s triad: 110
I. The endothelial layer of the blood vessels is injured/dysfunctional
II. Blood flow is compromised
III. Blood composition changes to hypercoagulability net
 
Multiple factors can compromise each of these three causes and thereby increase the 
risk of VTE. In the general population, intrinsic risk factors often trigger VTE in 
co-occurrence with either persistent or temporary provoking risk factors, although for 
about 50% of patients provoking factors are not identified.111-113 Genetic and intrinsic 
factors associated with VTE (not classifying events as provoked) are discussed first 
followed by a review of provoking factors. 
GENETIC RISK FACTORS FOR VTE
Various factors in the blood are important for thrombogenicity. Dysfunction or defi-
ciency of one of the important plasma coagulation inhibitors (loss-of-function mecha-
nisms) have large effects on the risk of VTE but are relatively rare in the population. 
Inherited insensitivity to endogenous anticoagulation mechanisms or increased levels 
of circulating prothrombotic factors (gain-of-function mechanisms) increases the risk 
of VTE more moderately but are more prevalent in the population.114 
In the general population
Loss-of-function mechanisms
Antithrombin is a potent endogenous anticoagulant with inhibitory effect on throm-
bin as well as other coagulation factors.115 Antithrombin deficiency is associated with 
a more than 10-fold increased risk of VTE.116 Protein C and Protein S are vitamin 
K-dependent endogenous anticoagulants, which inactivates coagulation factors V and 
VIII thereby reducing thrombin generation, Protein S works as a co-factor to Protein 
C.117 Protein C and Protein S deficiencies increase the risk of VTE by 7-8 - fold com-
pared with subjects with no coagulation defect.118  These loss-of function thrombophi-
lias are however rare in the general population. The incidence of Protein C deficiency 
is 14-50 per 10 000 persons while Protein S and Antithrombin deficiency is seen in 
around 10 per 10 000 persons. In VTE populations, about 1-3% have a loss-of-func-
tion thrombophilia.114
Gain-of-function mechanisms
The most frequent gain-of-function mechanism in the general population is non-O-
blood type, which is found in more than half of the population.119 Individuals with 
non-O blood type have higher levels of von Willebrand factor and coagulation factor 
VIII120  which is believed to be one of the reasons for their 1.5-2.5 - fold higher risk of 
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VTE compared with subjects with blood type O. Other factors must however contri-
bute because the association with non-O blood type remains after adjustment for von 
Willebrand factor and factor VIII levels.119,121,122 In addition, the ABO locus is associ-
ated with levels of inflammatory molecules, which may also contribute to the effect of 
blood type on the risk of VTE.123 
Coagulation factor V is a co-factor to factor activated factor X. This complex facilita-
tes the activation of prothrombin to thrombin. Furthermore, factor V acts with Protein 
C and Protein S on the degradation of activated factor VIII.124 Different variations in 
the gene encoding factor V, of which the factor V Leiden mutation is the most com-
mon, results in a lower rate of degradation of factor V and abnormal degradation of 
factor VIII.114,124 The factor V Leiden mutation is present in populations of European 
ancestry, where the prevalence is 5-10%.125,126 The risk of VTE is increased by 10-
80 - fold in case of homozygosity, while the risk of VTE is increased by 2-5 - fold in 
the more common case of heterozygosity compared with subjects free of the factor V 
Leiden mutation.119,126,127 Among VTE patients, 18% have the factor V Leiden allele.114 
Prothrombin is the inactive precursor of thrombin, which is responsible for the con-
version of fibrinogen to insoluble fibrin. Mutation in the untranslated part of the pro-
thrombin gene (G20210A) results in increased levels of circulating prothrombin.128 The 
G20210A mutation in the prothrombin gene is seen in 1-3% of the general population 
of European ancestry. The age and sex adjusted HR of VTE is 1.5 for heterozygote 
subjects, while in the very rare occasion of homozygosity the HR of VTE is 10 com-
pared with subjects without the mutation.119 The mutation is present in 6% of patients 
with VTE.114 
Few individuals carry more than one prothrombotic mutation.  In a study of 2310 VTE 
patients and 3204 controls, double heterozygosity was found in 2.2% of the cases, 
whose odds ratio (OR) for VTE was 20 (95% CI, 11.1-36.1).127
In cancer patients
Even though cancer is a tremendous provoking factor, genetic factors may not be a 
negligible in the assessment VTE risk in cancer patients. Several studies have shown 
that cancer patients with inherited thrombophilia (the vast majority being the factor V 
Leiden mutation) have a 2-7 - fold increased risk of VTE compared with cancer pa-
tients without thrombophilia.129-133 Few studies have assessed if ABO blood group have 
an effect on the risk of VTE in cancer patients. A single center study of 130 glioma 
patients found 3-9 - fold higher risk of VTE in patients with non-O blood type.134 In a 
study of 670 patients with pancreatic cancer, the OR of VTE in subjects with non-O 
blood type was 1.74 (95% CI, 1.07-2.84) in a multivariable model.135
INTRINSIC RISK FACTORS FOR VTE
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Besides the genetic factors described above, several characteristics of the patients are 
related to their risk of VTE. These intrinsic factors are reviewed below for both the 
general population and cancer patients.
In the general population
The risk of VTE differs by sex and age in the general population, the association is 
however not simple. Overall, the risk of VTE increases by increasing age. In a popu-
lation-based study from the US, incidence rates of VTE were 7-10 - fold higher in age 
groups above 75 years compared with those below 55 years. In the STAC cohort, the 
IR of VTE among subjects aged 20-29 years was 0.3 per 1000 PY, while it was 6.4 per 
1000 PY in subjects above 80 years.66 The increasing risk of VTE with higher age is 
not merely due to more cancers in the elderly population. In the Tromsø study, cancer 
was regarded a time-varying exposure. The HR of VTE in cancer patients <50 years 
was 20.5 compared with cancer free subjects after adjustment for cardiovascular risk 
factors, while in cancer patients ≥70 years the HR of VTE was 3.2 compared with can-
cer free subjects. The proportion of VTE that would not occur if cancer was eliminated 
in the population (i.e. the population attributable risk fraction) was however similar in 
the young and elderly age groups (14% and 18%, respectively).136  
In the general population, the effect of sex on the risk of VTE is dependent of age. In 
a French population based study, IRs of VTE increased with increasing age, however 
women had a higher IR of VTE than men when younger than 40 years of age and ol-
der than 75.44 In a population based VTE cohort from the UK, similar age dependent 
increase in the IR of VTE was observed, and with higher IRs of VTE in the youngest 
and oldest women compared with men.14 Increased risk of VTE among users of oral 
contraceptives contributes to these observations. A recent Cochrane review found the 
use of combined oral contraceptives associated with a relative risk of VTE of 3.5% 
(95% CI, 2.9-4.3).137 Pregnancies and puerperium also plays a role in the higher risk 
of VTE in younger women, and this is further elaborated in the section “Provoking, 
transient risk factors (non-cancer)” below. Among post-menopausal women, the use 
of hormone replacement therapy is associated with a doubling of the risk of VTE, 
however varying by type of hormone and route of administration.138-140 Regarding the 
middle-aged, (around 50-70 years of age) men seem to have an increased risk of VTE 
compared with women6,44,141 This association was explained by the effect of increasing 
height on the risk of VTE in one of the studies as the association disappeared after 
adjustment for body height.141 In the Tromsø study, a HR of VTE of 1.3 was observed 
per 10 cm increase in body height for men.84 A recent meta-analysis of three cohorts 
also observed a 30-40% increased risk of VTE per 10 cm increase in height. The asso-
ciation remained after adjustment for genetic variants related to body height. Possible 
explanations could be combinations of higher resting venous pressure and thereby more 
damages in the vessels and a larger venous surface including more and larger venous 
valves, where the venous thrombosis can form. 142 Obesity (body mass index 30 > 
kg/m2) has been associated with 2-3 - fold increased risk of VTE in population based 
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studies.54,143,144 Potential confounding by cardio metabolic consequences of obesity on 
the risk of VTE was investigated in the Tromsø study.145 No such confounding was 
observed, and the authors speculate that the increased risk of VTE in obese subjects 
could be due to obesity induced stasis or circulating adipokines. 
In a meta-analysis of prospectively collected data from nine population based studies 
with 5000 validated VTE events among 245 000 subjects, modifiable classical cardi-
ovascular risk factors were not associated with the risk of VTE except for smoking, 
whose effect could be mediated through cancer.146 
A history of VTE is one of the strongest risk factors for VTE. The OR for a new VTE 
was 15.6 (95%CI, 6.8-35.9) in subjects with a history of VTE in a multi-center case 
control study with prospectively collected data from of 636 non-hospitalized DVT pa-
tients and 636 controls matched on age and gender.147 It is not clearly understood why 
previous VTE predisposes to new VTEs, but it is established that elevated D-dimer can 
be used as a predictor of recurrence in patients with pulmonary embolism.148
In cancer patients
The association with age remains in cancer populations. Several studies have reported 
that the risk of VTE is higher in cancer patients above 60-65 years than in younger 
cancer patients.25,26,69
Several large studies assessed the impact of sex on the risk of VTE in cancer popula-
tions and found no effect.24,87,88,132,149-151 In a few studies, female gender was associated 
with 14-40% higher risk of VTE compared with male.69,90,152 None of these observati-
ons were however further explained. 
Obese breast cancer patients are at higher risk of VTE than those with ideal body 
weight. Among 13 202 breast cancer patients in the UK, the HR of VTE increased 
with increasing body mass index after adjustment for age, comorbidities, cancer spe-
cific factors and associated treatments. Highest HR of VTE was observed on morbid-
ly obese patients compared with ideal weight (HR 3.0, 95% CI, 2.1-4.4).153 The same 
tendency towards a “dose dependent” increase in the risk of VTE was observed in a 
cohort of colorectal cancer patients from the UK, where the HR of VTE in morbid-
ly obese patients compared with ideal weight was 2.0 (95% CI, 1.2-3.2).154 Also in a 
study including 516 stage II and III colorectal cancer patients, an increase in the body 
mass index of 5 kg/m2  was associated with a SHR for VTE of 1.6 (95% CI, 1.2-2.0).155 
Smoking has been investigated as a possible risk factor for VTE in a few cancer popu-
lations. In colorectal cancer the HR of VTE in smokers/ex-smokers was 1.7 (95% CI, 
0.4–6.7) compared with never smokers.155 Among 422 lymphoma patients exposed to 
chemotherapy at the MD Anderson Cancer Center in 2003, former smoking was not 
associated with VTE.156 In lung cancer patients, smoking was not associated with the 
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risk of VTE after controlling for age, body mass index, comorbidities, cancer specific 
factors and associated treatments (HR 1.2, 95% CI, 0.9-1.5).86
Several studies found no effect of comorbidities or performance status of cancer pa-
tients’ risk of VTE.86,132,150,153-155,157-159 This might however differ according to cancer 
type in the sense that the effect of cancer on the risk of VTE exceeds that of comor-
bidities in aggressive cancer types, whereas in less aggressive cancer types the effect 
of comorbidities on the risk of VTE is on par with or even exceeds that of the can-
cer. A study of 16 755 Californian lymphoma patients found that increasing number 
of comorbidities was a strong predictor for VTE in low grade lymphomas, whereas 
comorbidities did not affect the risk of VTE in high grade lymphomas.151 A nationwide 
study of all Danish prostate cancer patients diagnosed between 1995-2011 showed a 
considerable interaction between prostate cancer and comorbidity levels after cancer 
diagnosis accounting for 30% of all VTEs among prostate cancer patietns.81
A history of VTE is one of the strongest risk factors for a new VTE in association with 
cancer. The risk of VTE after the cancer diagnosis was increased by 12-15 - fold in 
case of previous VTE in recently published studies.160,161 The competing risk of death 
was accounted for in a study of VTE among 2730 lymphoma patients in the Veteran’s 
Administration Cancer Registry; the SHR of VTE was 4.73 (95% CI, 2.5-9.0) in case 
of a history of VTE.162
In summary, genetic and intrinsic factors that do not classify VTE as a provoked event 
have substantial impact on the risk of VTE in both the general population and in cancer 
patients. A history of VTE is one of the strongest risk factors for a new VTE in both 
the general population and cancer populations. Older age, obesity and genetic throm-
bophilias are also risk factors for VTE in both cancer populations and in the general 
population. 
PROVOKING, TRANSIENT RISK FACTORS (NON-CANCER)
Hospitalization, surgery and trauma
Hospitalization increases the risk of VTE dramatically in the general population. In 
a study based on review of medical records from residents of Olmsted County with 
VTE, the average age and sex adjusted IR of in-hospital VTE was  96 per 1000 PY 
while the IR of community acquired VTE was 0.7 per 1000 PY.163 Hospitalization li-
kewise increases the risk of VTE in cancer patients. In a case-control study including 
570 cases with active cancer associated VTE and 604 controls with cancer, the OR of 
VTE in case of hospitalization was 7.9 (95%CI, 4.4-14.1).164 
Approximately 200 000 VTE-related deaths occur annually in the US, one-third of the-
se follow surgery.165 About 50% of in total 68 183 hospitalized patients were at risk of 
VTE in a multinational cross-sectional study on hospitalizations in 358 sites during the 
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last five months of 2006. Forty-two percent of medical patients were at risk of VTE, 
while 64% of surgical patients were. However, only 59% of the surgical patients at 
risk of VTE received guideline-recommended thromboprophylaxis.19 The risk of VTE 
differs according to type of surgery. The 3-month risk of hospitalization for VTE is hig-
hest among patients undergoing neurosurgery, total hip arthroplasty, cystectomy and 
major vascular surgery.166 In a recent study of 12 388 patients undergoing colectomy, 
the overall IR of VTE within the first year after surgery was 30 per 1000 PY. The risk 
of VTE was 2.2-fold higher for patients undergoing acute colectomy compared with 
elective procedures. Interestingly, the risk of VTE in the first month after surgery was 
similar in cancer and non-cancer patients undergoing emergency colectomy.167 Even 
despite thromboprophylaxis in the immediate postoperative period, the 3-month cumu-
lative incidence of VTE following surgery was 2-3%.168 
Trauma patients have a high risk of VTE. Among 349 trauma patients who did not 
receive thromboprophylaxis, DVT was diagnosed in nearly 60% by contrast venograp-
hy 1-3 weeks after the admission.169 In a recently published study of trauma patients 
expected to be admitted to an intensive care unit for more than 48 hours and given 
protocol-driven thromboprophylaxis,VTE was found by repeated screening in 31% of 
the study subjects during a median follow-up of 7 days.170
Infection
Infections transiently increase the risk of VTE in both hospitalized and non-hospita-
lized patients. In the Tromsø study it was recently observed that hospitalization due 
to infection lead to a 15-fold increased risk of VTE after adjustment for immobiliza-
tion while in mobile patients hospitalized for infection, the risk of VTE was 20-fold 
increased compared with control periods.171 The incidence rate ratio (IRR) of VTE 
within three months after hospital diagnosed infection was 3.3 (95% CI, 2.9-3.8) after 
adjustment for cancer, pregnancy, surgery and trauma in a Danish population based 
case-control study. For infections diagnosed and handled in the primary sector, the 
adjusted IRR of VTE was 2.6 (95% CI, 2.5-2.8).172 The impact of infections in the 
community on the risk of VTE was also demonstrated in a self-controlled study of 
11 033 VTE patients. The risk of VTE was significantly higher up to 26 weeks after a 
urinary or respiratory tract infection compared with before infection. Age adjusted IRs 
for VTE in the first two weeks after infection were 2 for both urinary tract and respi-
ratory tract infections but fell with successive time since infection reaching the initial 
risk one year after the infection.173
Immobilization
Voluntary or involuntary transient immobilization reduces the blood flow in the ven-
ous system, which results in markedly increased risk of VTE in these settings or con-
ditions. Immobilization increases the risk of VTE in the background population (OR 
6.2 [95% CI, 5.4-7.0]) and even more among patients with major illnesses as liver and 
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kidney diseases, heart failure or arterial thrombosis (OR 10.4 [95% CI, 7.5-14.4]).174 
In a cohort of 8 755 employees of international organizations, the IR of VTE in asso-
ciation with air travel of more than four hours duration was 3.2 per 1000 PY, which 
was 3.2-fold higher compared with individuals not exposed to air travel. Concomitant 
use of oral contraceptives, repeated exposure to air travel, longer duration of air tra-
vels, and overweight were all associated with further increased risk of VTE during air 
travel.175 In a study of 197 cases with VTE and 197 controls with other thrombotic 
diseases, the OR of VTE was 2.8 (95% CI, 1.2-6.1) if exposed to prolonged sitting in 
association with work or use of computers.176 Below-knee cast immobilization increa-
ses the risk of VTE by 8-fold, with higher risks in those with traumatic indications for 
cast immobilization.177 
Pregnancy and puerperium
Pregnancy and puerperium increases the risk of VTE by 4-6 - fold compared with non-
pregnant women, especially obese women, those having cesarean delivery, preeclamp-
sia or infections postpartum are at risk of VTE.178-180
PROVOKING, PERSISTENT RISK FACTORS (NON-CANCER)
Several non-malignant, chronic conditions increase the risk of VTE considerably. 
Chronic inflammatory bowel disease increases the risk of VTE by 3-9-fold dependent 
of disease activity.181 Chronic renal diseases are associated with increased risk of VTE. 
In a recently published study of 3564 Taiwan patients with end-stage renal disease and 
controls matched on age, sex and index-year, the HR of DVT in the end-stage renal 
disease group was 13.9 after adjustment for comorbidities.182 Even decreases in the 
estimated glomerular filtration rate in the normal spectrum was independently associ-
ated with VTE in a pooled analysis of data from five large population based cohorts.183 
Neurological diseases resulting in extremity paresis is associated with a high risk of 
VTE.184 In a prospective study of 94 patients with spinal cord injury who all recei-
ved thromboprophylaxis, 23% had a VTE within a median follow-up of 36 months. 
Previous VTE and paraplegia were associated with a 5-6-fold higher risk of VTE in 
this population.185
CANCER SPECIFIC RISK FACTORS
Active cancer is regarded a provoking, persistent risk factor for VTE in the definition 
proposed by ISTH.48 Uncured cancer and ongoing curative treatment is considered ac-
tive cancer in this classification. Cancer is no longer considered a provoking factor if 
cured. The time interval from last treatment to certainty of cure is, however, not easily 
standardized, and it is dependent of both cancer specific factors and treatment type. 
The impact of cancer characteristics, cancer relapse or additional cancer and cancer 
related treatments on the risk of VTE is reviewed below. 
BACKGROUND
31
Cancer type
Population based studies including multiple cancer types do consistently report lar-
ge variation in the risk of VTE according to cancer type, typically with lower risk in 
less aggressive cancer types as breast and prostate cancer, and higher risks in cancer 
types with a more aggressive phenotype such as pancreas, brain, ovary and bone can-
cer.25,26,28,68,69,76,149,186 A large meta-analysis from 2012 based on data from 38 studies 
reporting VTE risks for both single and multiple types of cancer showed that the IR 
of VTE in prostate and breast cancer were around 10 per 1000 PY, while in brain and 
pancreas cancer the IR was more than 50 per 1000 PY( Figure 1).79 A recent study ba-
sed on data from the STAC cohort highlights the importance of inclusion of mortality 
rate when estimating the risk of VTE in cancer populations.27 In the standard 1-KM 
approach, the 2-year cumulative incidence of VTE ranged from 1% in breast cancer 
to 10 % in pancreas cancer, while the range narrowed to 1 - 4% when taking the com-
peting risk of death into account. This means that the effect of cancer type remains in 
analysis taking the competing risk of death into account, but it suggests that previously 
observed dramatic effects of cancer type might be overestimated due to considerable 
mortality in some cancer types, leading to informative right censoring.
Figure 1. Figure S1 from Horsted et al. 79 showing pooled IRs of VTE for several cancer types 
based on data from studies where follow-up commenced at the cancer diagnosis. Number of 
studies contributing to each estimate are given in the brackets.
Estimates of VTE occurrence in recently published studies concerning single cancer 
types with study entry at cancer diagnosis are summarized in Table 2. Despite the 
same time of start of follow-up (i.e. at the time of cancer diagnosis) in these studies, 
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the provided VTE risk estimates can be difficult to compare due to different definitions 
of VTE, study methods and lengths of follow-up. The risk estimates do however refle-
ct the findings from the aforementioned studies encompassing multiple cancer types 
and the meta-analysis, with 2-year risks of 1-2 % in breast and prostate cancer while 
higher estimates are seen in endometrial, ovarian, hematological, lung and colorectal 
cancer. The majority of studies provide cumulative risk estimates including events in 
close proximity to the cancer diagnosis with no or limited detailed information about 
risks of VTE beyond the period in closest proximity to the cancer diagnosis (Table 
2).80,81,153,154,157,158,160,187-189 In the study by Walker et al., the cumulative 2-year risk of 
VTE was 4.9%, but 58% (135 out of 232) of the events that contributed to this occurred 
within the first 6 months after cancer diagnosis.154 Similarly, in the study by Rodriguez 
et al., the 2 - year cumulative incidence of VTE was 2.7%, however, 44% of the VTEs 
included in this estimate occurred within the first three month after the cancer diag-
nosis.188 Given the large impact of time since cancer diagnosis actually described in 
most of these studies, it is relevant to provide estimates based on events occurring in 
different time intervals since cancer diagnosis in addition to estimates based on events 
that occurred within the first months after the cancer diagnosis. Fewer studies had this 
focus, and estimates based on total study time from the cancer diagnosis and onwards 
are consistently higher than the estimates restricted to 6-12 months after the cancer 
diagnosis and onward (Table 2).86-88,90,150-152,162 This shows that the typically reported 
2-year risk estimates are not only possibly high due to the competing risk of death in 
some cancer types, but also due to inclusion of events in close proximity to the cancer 
diagnosis. When focusing on estimates of VTE within the first few months after can-
cer diagnosis, the risk however still differs markedly with cancer type, from 2.5% in 
breast cancer, 7.2% in lung cancer to 19.2% in leukemia and possibly higher in lymp-
homa (Table 2). However, some of the studies in Table 2 probably overestimate the 
risk of VTE to some degree as only few of them treated death as competing risk when 
estimating cumulative incidences.81,150,162 
Cancer stage
Several studies encompassing many cancer types, have reported that the risk of VTE 
is 2-19 - fold higher in distant metastasis compared with the general population24 or 
localized disease.28,129,190 However one study reported varying effects of cancer stage 
on the risk according to cancer type with highest effect in melanoma and bladder can-
cer and lower in lymphoma and prostate cancer.76 Regional stage is associated with a 
1.1-3.7 - fold higher risk of VTE compared with the general population or localized 
disease,24,190 also varying by cancer type.76  Different definitions of cancer stage com-
plicates comparison of effect estimates in these studies, however there seems to be a 
consistent and “dose dependent” effect of cancer stage on the risk of VTE. 
In the studies of single cancer types in Table 2, the consistency and “dose dependency” 
is however not confirmed for all cancer types: In breast cancer Chew et al.187 found 
considerable effect of regional spread (HR 2.1 [95% CI, 1.8-2.3]) and even higher of 
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distant metastasis (HR 6.3 [95% CI, 5.3-7.5]) on the risk of VTE, while the effect of 
extent of breast cancer was more moderate in the studies by Walker et al. and Brand 
et al.153,160 Similarly, in lung cancer the HR of VTE in regional stage was 2-fold hig-
her in regional stage and 4-fold higher in distant metastasis compared with localized 
disease in the study by Chew et al., while the effect estimates were more modest and 
more similar in regional stage and distant metastatic lung cancer in the study by Walker 
et al.86 High stage in colorectal cancer was associated with a 3-fold increased risk of 
VTE, while moderate disease extension was associated with a 2- fold increased risk 
of VTE compared with localized disease in both UK and US study populations.88,154 
For lymphoma and prostate cancer, the effect of disease extension is more moderate 
in all the studies in Table 2.
The competing risk of death may to some degree explain the dramatic effects of di-
stant metastasis on the risk of VTE in some of the referred studies. The mortality for 
cancer patients with distant metastasis is higher than for those with localized disease, 
and this would introduce informative right censoring if death is not treated as compe-
ting risk. The absolute risk of VTE in case of distant metastasis was higher in studies 
not accounting for the competing risk of death.86-88,90,154,187-189 However, both Lund et 
al. and Sanfilippo et al. found lymphoma stage associated with a higher risk of VTE 
treating death as competing risk in absolute and relative association measures; stage 
III/IV compared with stage I/II was associated with a 1.1 -1.5 - fold increased risk of 
VTE (Table 2)150,162 
In summary, the reviewed literature shows that cancer stage has an impact on the risk 
of VTE, which is, however, however also influenced by the cancer type despite possi-
ble overestimation due to the competing risk of death.
Differentiation or histology of cancer cells 
Several authors have speculated that the main contributor to VTE in cancer could be 
the aggressiveness of the cancer.24,85,88,190,191 The degree of differentiation (tumor gra-
de) and the histology are important markers for the aggressiveness of the tumor.192 
For this reason, Ahlbrecth et al. investigated the impact of tumor grade on the risk of 
VTE in cancer patients based on data from the CATS study, and found high grade tu-
mors associated with a 2-fold higher risk of VTE compared with low grade tumors.193 
The absolute risk of VTE was however high for both high grade tumors and low gra-
de tumors after 6-months (8.2% and 4.0%, respectively), and possibly overestimated 
because the competing risk of death was ignored. 
Many of the studies in Table 2 investigated the effect of tumor grade or histology on 
the risk of VTE. The risk of VTE was higher in case of aggressive histology or poor 
differentiation of cancer cells in lung cancer, uterine cancers and lymphoma.  Lund 
et al. and Sanfilippo et al. both found histology associated with VTE treating death as 
competing risk. In the study by Sanfilippo et al., the SHR of VTE in diffuse large B-cell 
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lymphoma was 1.5 (95% CI, 1.0-2.4) compared with follicular lymphoma, which was 
quite similar to the SHR of VTE in diffuse large B-cell lymphoma versus follicular 
lymphoma in the study by Lund et al. (1.8 (95% CI, 1.3-2.4).150,162 Tumor grade and/or 
histology was not associated with the risk of VTE in either of the studies concerning 
leukemia, bladder, colorectal and breast cancer (Table 2). 
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Cancer recurrence or additional cancer
The risk of VTE in cancer patients who are diagnosed with a second primary cancer 
or have relapse of the first one is not investigated to the same extent as the association 
between the first cancer diagnosis and VTE. A few studies have reported some infor-
mation regarding the incidence or impact of additional or recurrent cancer in studies 
of cancer-associated VTE. 
In the study concerning ovarian cancer by Rodriguez et al., 5% of those with VTE had 
a second primary malignancy, while in the study by Simkovic et al. 24% of CLL pa-
tients with VTE were registered with a second malignancy.132,189 Among 516 patients 
with colorectal cancer, the overall VTE risk was low, however the HR for VTE was 
13.0 (95% CI 4.4-38.7) in case of colorectal cancer recurrence.155
Multiple active cancers is associated with higher risk of VTE recurrence. In a popu-
lation of VTE patients, the HR of recurrent VTE in case of multiple cancer types was 
5.1 (95% CI, 2.2-11.5) compared with cancer free VTE patients, while for cases with 
a single cancer the HR of recurrence was 2.6 (95% CI, 2.0-3.4).194  Chee at al. investi-
gated VTE recurrence predictors in a cohort of patients with cancer-associated VTE.94 
In a multivariate model, the HR of recurrence was 1.8 (95% CI, 0.9-3.6) in case of 
multiple active cancers. 
These sparse observations indicate that cancer recurrence or exposure to secondary 
malignancy may be associated with the risk of VTE. However, this topic needs further 
investigation.
Biomarkers for cancer-associated VTE
Several biomarkers have been proposed for prediction of VTE in cancer patients, espe-
cially thrombocytosis, leukocytosis and anemia have been correlated to VTE in cancer 
populations.195-197 However, many studies on single cancer types reported either simil-
ar distribution of hemoglobin, thrombocyte and leukocyte count in patients with VTE 
compared with patients without VTE198,199 or no effect on relative estimates.86,150,156,162 
Furthermore, the effects of thrombocytosis, leukocytosis and anemia was surpassed 
by D-dimer levels and P-selectin in the Vienna CATS study.190,200 Nationwide registri-
es usually do not include continuous laboratory variables, and large population based 
studies concerning the role of laboratory parameters in cancer-associated VTE are thus 
lacking in the existing literature.
CANCER TREATMENT RELATED FACTORS
Cancer treatment encompass several modalities as surgery, radiation therapy, chemo-
therapy, endocrine treatment, immunomodulatory agents and combinations hereof – 
sometimes administered through indwelling catheters. Furthermore, supportive treat-
ment with blood transfusion and use of erythropoiesis stimulating agents are provided 
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in some occasions. These factors can influence the risk of VTE in cancer patients.
Cancer patients exposed to chemotherapy have a 6-16 - fold higher risk of VTE com-
pared with the background population,24,201 while the risk is about 2-fold higher for 
cancer patietns not exposed to chemotheraphy.28,69,149,186 The risk of VTE was 1.5-10 
-  fold higher for those exposed to chemotherapy compared with unexposed in most 
of the studies reviewed in Table 2.86,150,153,154,158,160,162 In general, cancer patients with a 
central venous catheter have a 6-7% risk of VTE. The risk of VTE is 2-fold higher 
in case of peripherally inserted catheters compared with centrally inserted catheters.202 
The risk of VTE was a higher in AML patients with a central venous catheter for admi-
nistration of chemotherapy than in those with no central venous catheter, particularly 
the risk of upper extremity thrombosis (HR 3.4 [95% CI, 1.8-6.5]).152 
In the recently published study by Blix et al.,27 the risk of VTE was similar in the 6 
months before cancer diagnosis and in the initial 6 months after the cancer diagnosis 
when accounting for the competing risk of death in the regression analysis. Based on 
this observation, the authors speculate that the risk of VTE in cancer is more related 
to the cancer itself rather than chemotherapy and other factors related to diagnosis and 
treatment of cancer, however they were unable to demonstrate this due to lack of infor-
mation about these factors. Other recent studies including information about chemothe-
rapy showed either significantly lower risk of VTE during exposure to chemotherapy203 
or no association between chemotherapy and the risk of VTE.132,155 These studies are 
small but nonetheless indicate that the effect of chemotherapy does not simply increase 
the risk of VTE in all cancer types. 
Endocrine treatment increases the risk about 2-fold in breast cancer patients.153,160 
In the study by van Hemelrijck et al., the absolute risk of VTE was higher in prostate 
cancer patients compared with the general population, however only for prostate cancer 
patients on endocrine treatments (absolute risk difference for VTE was 3.7, 95% CI 3.0-
4.3) while the difference in VTE risk for prostate cancer patients in surveillance and the 
general population was 0.3 (95%CI, -0.01-0.5).80 This indicates that the disease does 
not contribute as much as the endocrine treatment to the risk of VTE in prostate cancer. 
Several studies have shown that myeloma patients treated with immunomodulatory 
therapy in combination with dexamethasone have a considerable risk of VTE, and 
routine thromboprophylaxis is therefore recommended for this group of patients. 204-206
The effect of radio therapy on the risk of VTE is assessed in a few studies and there 
is no consistent, strong association with VTE,28,200 which is also reflected in the varying 
effect estimates in Table 2.28,86,150,158,160 Exposure to erythropoietin (OR 1.3-1.6)161,207 
and blood transfusion (OR 1.6-2.3)161,208 is associated with increased risk of VTE in 
cancer patients.
Cancer patients have a 4-fold higher risk of fatal PE in association with general sur-
gery compared with non-cancer surgical patients.209 However, if confined to cancer 
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surgery (e.g. mastectomy in breast cancer), lower risk of VTE after surgery is seen in 
many studies (HRs 0.4 -0.7).87,88,187,189 In these studies, cancer surgery is a proxy for 
less extensive cancers in typically younger patients with better performance status. 
In summary cancer itself increases the risk of VTE, however the impact is difficult 
to separate from contributions from cancer treatment modalities and supportive care. 
Central venous catheters, endocrine and immunomodulatory treatments increased the 
risk of cancer-associated VTE most consistently in the reviewed literature. 
PREDICTION OF VTE IN CANCER PATIENTS
The risk of VTE in cancer patients is influenced by intrinsic factors, provoking fac-
tors and cancer specific factors. Several models for assessment of the risk of VTE in 
single cancer types210-212 and in non-hospitalized cancer patients have been developed 
during the last decade including a selection of these factors. The Khorana score195 was 
the first risk assessment model upon which several subsequent risk assessment model 
have been built213-216 (Table 3). The risk assessment models all include cancer speci-
fic factors. Definitions of “very high risk” and “high risk” cancer types vary by study 
population, but all models except the COMPASS-CAT217 includes cancer type as an 
item. Also, biomarkers were included in all the models. The COMPASS-CAT217, the 
TiC-Onco218 and the simple Vienna CATS219 included only one biomarker, and the 
remainder included more than one. All models but the simple Vienna CATS included 
intrinsic factors. A history of VTE was only included in ONCOTEV216 and COMPASS-
CAT.217 Items related to the treatment of cancer were included in several of the models, 
however for the Khorana model and the models based hereon restricted to treatment 
with erythropoietin. Only two models included information about anti-cancer treat-
ment (PROTECHT and COMPAS-CAT) 214,217 Time since cancer diagnosis was only 
included in the COMPASS-CAT model.
External validation of the risk assessment models can confirm their usefulness in the 
clinic and in trials, however many of the models perform sub optimally.77,212,220-225 
Recently, the Khorana score, the Vienna CATS, PROTECHT and CONKO models 
were validated in a prospective, multinational cohort study. 35 The latter three tested 
models are modifications of the Khorana score (Table 3). In brief, the validation stu-
dy showed that all four models performed poorly, however the Vienna CATS and the 
PROTECHT models were useful for discriminating between cancer patients with high 
risk of VTE and cancer patients with low risk of VTE. In another recent validation 
study, however smaller, the Khorana score, PROTECHT, CONKO and COMPASS-
CAT models were tested in a cohort of 118 lung cancer patients among whom 20 VTEs 
occurred. 224 The sensitivity of a high COMPASS-CAT was 100% while for the other 
three models it was 10%-55%. 
Development of new or refinement of current risk assessment models will presumably 
continue. The risk of VTE in cancer differs markedly by both cancer specific factors, 
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cancer related treatments, intrinsic factors, time factors and events that occur after the 
cancer diagnosis, and the effect of these factors maybe even vary within narrow pe-
riods. This complexity will probably increase as we learn more and maybe reach an 
extent where one risk assessment model does not fit all cancer types.
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HYPOTHESES AND AIMS
 
The incidence of VTE according to cancer stage has been investigated in large popula-
tion-based studies. However, the incidence of VTE has been assessed either for cancer 
stage with no regard to cancer type, or in single types of cancer per study. This leaves 
little or no opportunity to assess whether the impact of cancer stage might differ by 
cancer type. The null hypothesis of study 1 was that the risk of VTE was similar across 
initial cancer stage. The aim of study 1 was accordingly:
Study 1:
To investigate the incidence of VTE according to initial cancer stage in different types 
of solid cancer in a large population-based cohort.
 
The risk of VTE in hematological cancers have been investigated in studies combining 
the different types of hematological cancer in one group, or in studies concerning only 
one or a few similar types of hematological cancer. Current knowledge of which types 
of hematological cancers contributes to the overall high risk of VTE in the group of 
hematological cancer is sparse. The null-hypothesis of study 2 was that the risk of VTE 
was similar across subtypes of hematological cancers. The aim of study 2 was hence:
Study 2:
To investigate the incidence of VTE according to type of hematological cancer by 
comparison with cancer free reference subjects matched on age and gender in a popu-
lation-based cohort.
The chronic nature of some cancer types and recent improvements in cancer treatments 
leads to increasing numbers of individuals who live with chronic cancer or survive 
acute cancer types. The risk of VTE in cancer patients has typically been investigated 
in close proximity to cancer diagnosis. The null-hypothesis of study 3 was that the risk 
of VTE attenuated to levels observed in the general population for all cancer types. 
The aim of study 3 was therefore:
Study 3:  
To investigate the risk of VTE in cancer patients who survived to two years after can-
cer diagnosis without VTE compared with cancer-free reference subjects in a popu-
lation-based cohort.
In study 2 we observed surprisingly high IR of VTE among CLL patients. Two small 
studies have also reported high risk of VTE in CLL, however the impact of CLL pro-
gnostic factors and treatments was not exhaustively investigated. No prior studies have 
assessed the validity of VTE diagnoses in CLL patients. The null hypothesis of study 4 
was that the risk of VTE was similar in CLL patients with regard to both patient speci-
fic characteristics and CLL prognostic factors. The aims of study 4 were:
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Study 4:  
To assess the validity of VTE diagnoses among CLL patients and to investigate if the 
risk of VTE was associated with CLL treatment periods, patient specific and CLL pro-
gnostic factors, and if VTE was associated with the mortality of CLL patients. 
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45
METHODS
STUDY POPULATIONS
Study 1-3 were based on data from a large Danish-Norwegian population-based data-
base - the STAC cohort. The main research question in study 4 was investigated based 
on data from all Danish CLL patients, while the validation of VTE diagnosis codes 
within study 4 was based on a local Danish CLL cohort. These three study populations 
and the sources of data herein are further described below.
THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) 
COHORT
Study 1-3 are based on data from the STAC cohort, which was established in 2011 with 
the main objective to investigate VTE in cancer patients. The STAC cohort consists 
of data collected in three large population-based cohorts established in the mid-1990’s 
in order to investigate the epidemiology of cardiovascular and chronic diseases and 
health related lifestyle (Tromsø and HUNT) and associations between lifestyle factors 
and cancer plus chronic diseases (DCH) in the populations.226-228  Inhabitants of the 
municipality of Tromsø and Nord-Trøndelag County (HUNT) in Norway, and urban 
areas of Aarhus and Copenhagen in Denmark (DCH), respectively, were invited to 
participate. The study entry periods and dates for complete follow-up varied a little in 
the three original cohort studies, as did the age of the invited participants (Table 4). 
The earliest study entry was December 1993 in the DCH study, and the most recent 
last date of follow-up was for VTE was December 2012 in the Tromsø study. Study 
participants with cancer or VTE before study entry in the three original cohorts were 
excluded before merging of the three original cohorts. The STAC cohort accordingly 
includes person-time data of 144 952 subjects with a median age at study inclusion of 
53 years and a minor overweight of female participants (52.6%). Information about 
socio-economic conditions, health status and anthropometric measures were obtained 
at baseline in all three original cohorts. All VTEs were objectively confirmed, as de-
scribed below. Further details of the STAC cohort are published.66 
Table 4. Overview of the three cohorts contributing with data to the STAC cohort.
Original 
cohort
No. of
participants
No. excluded from 
merging due to 
previous cancer or
VTE
Age of 
participants at 
study entry
(years)
Study
enrollment
Last date of follow-up for
VTE Cancer Death or 
migration
DCH 57 053 1040 50 - 64 1993 – 1997 30.04.2008 30.04.2008 01.07.2013 
Tromsø 27 158 1065 25 - 97 1994 – 1995 31.12.2012 31.12.2012 31.12.2012
HUNT 65 237 2391 19 – 103 1995 – 1997 31.12.2007 31.12.2009 31.12.2010
VENOUS THROMBOEMBOLISM IN SOLID AND HEMATOLOGICAL CANCERS
46
THE DANISH NATIONAL CHRONIC LYMPHOCYTIC LEUKEMIA 
REGISTRY
Study 4, concerning VTE in CLL patients was based on data from the Danish National 
CLL Registry where clinicopathological characteristics of all patients diagnosed with 
CLL in Denmark since 2008 have been registered. In addition to the date and ICD-10 
diagnosis code, also the clinicopathologic features, date and type of first line treatment 
and response hereto is recorded. The CLL-treating hematologists in the nine hema-
tology centers in Denmark prospectively collect these data.229 The coverage of the 
CLL registry was >99.0% in the years 2012 – 2014, for 2015 it was 98.7%. The data 
completeness was 98.7%, 92.7%, 84.2% and 59.6% for patients registered in 2012, 
2013, 2014 and 2015, respectively. Regular cross-referencing with the Danish National 
Patient Registry (DNPR) ensures continuous updates and ongoing improvement of the 
data completeness in the Danish National CLL Registry.230 
The Danish National Patient Registry and the Civil Registration 
System
The Danish hospitals are tax-funded based on each patient contact and the diagnoses 
and procedures in association hereto. This information is gathered in the DNPR for 
this purpose.231 The DNPR was established in 1977. Until 1995, person level data from 
each hospitalization was registered and from 1995, ambulatory contacts were included 
in addition. More than 99% of all contacts to the Danish health care system is captu-
red in the DNPR.232 Patients cannot have a contact with the Danish health care system 
without registration by the civil personal registration number in the DNPR. The ci-
vil personal registration number is a unique ten-digit numeral code assigned to every 
Danish resident at birth or immigration by the Danish Civil Registration System that 
keeps track of vital status, moving within Denmark as well as in and out of the coun-
try.233 The civil personal registration number is used for linkage of informations from 
all Danish registries at a person level.
LOCAL DATASET FROM AALBORG UNIVERSITY HOSPITAL
The validation of VTE diagnosis codes among CLL patients was based on a local 
dataset containing the patients diagnosed with CLL from 2008 to 2016 at Aalborg 
University Hospital. The regional data protection agency approved the study (project 
id-number 2017-93). The treatment and care of CLL patients from the North Denmark 
Region have been centralized at the Department of Hematology at Aalborg University 
Hospital since 2008. The medical records, biochemical tests and diagnostic images plus 
other clinical and para-clinical information of all patients treated in the North Denmark 
Region are embedded in the electronic patients system Clinical Suite operated by CSC 
Scandihealth. In Clinical Suite, both action and secondary diagnoses plus procedures 
related to diagnostics and treatments at person level are registered by use of the civil 
registration number, and subsequently reported to the DNPR.231
METHODS
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SOURCES OF INFORMATION
CANCER DIAGNOSIS
In the STAC cohort (study 1-3), information about cancer type, morphology, stage 
and date of diagnosis were obtained by linkage to the National Norwegian Cancer 
Registry for study participants from the Tromsø and HUNT studies and from the 
Danish National Cancer Registry for subjects in the DCH study. 
The Danish National Cancer Registry has collected data about cancer cases sin-
ce 1943, but in 1987 registration of cancer became mandatory by law. The Danish 
National Cancer registry used the ICD-O-1 (International Classification of Diseases for 
Oncology, 1st edition) codes from 1978 to 2003. From 2003 and onwards, the ICD-O-3 
(International Classification of Diseases for Oncology, 3rd edition, 1992) system was 
used for morphology and topography and the ICD-10 (International Classification of 
Diseases, 10th edition, 1990) codes was used for the disease classification. All the 
ICD-O-1 codes from previously registered cases were converted to ICD-O-3 and ICD-
10 codes.234
The Norwegian National Cancer Registry has systematically collected data on cancer 
cases since 1953, where notification became mandatory by law. The morphology and 
topography of tumors has been coded by the ICD-O-2 (International Classification of 
Diseases for Oncology, 2nd edition, 1992) from 1993. The ICD-O-3 has been used 
for non-solid tumors since 2002.235 Topography has been converted to ICD-10 termi-
nology from 2005 and onwards. 236
In summary, the National Norwegian and Danish Cancer registries both provide ICD-
10 and ICD-O-3 codes.234,236
In study 4, we received information about the CLL diagnosis from the Danish National 
CLL Registry, which is cross-referred to the DNPR as described in the paragraph con-
cerning the Danish National CLL Registry. The dataset from the Danish National CLL 
Registry was transferred to a server at Statistics Denmark for linkage to other national 
registries. Information about diagnosis date and type of cancer besides CLL (ICD-8: 
140-209, except 173.x and ICD-10: CC00-96) was retrieved from the DNPR by lin-
kage of the CLL patients’ civil personal registration numbers. 
CANCER STAGE
The exposure of interest was cancer stage (i.e. the extent to which the cancer has devel-
oped by spreading) in study 1. Cancer stage was described differently in the national 
Danish and Norwegian cancer registries: Two national principal systems including a 
“local”, “regional”, and “distant metastasis” nomenclature for description of cancer 
stage for solid tumors were used. In Norway, the Norwegian principal classification 
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system with 12 principal codes for disease extension was used throughout the study 
period for subjects in the STAC cohort.237 In Denmark, the Danish principal classifica-
tion system was used until 2004, except for the gynecological and colorectal cancers, 
where cancer stage has been coded by FIGO and Duke’s classifications, respectively 
until 2004. In 2004, the TNM Classification of Malignant tumors was introduced in the 
Danish cancer registry.238 Hence, in total five cancer stage classification systems had to 
be aligned in a common cancer stage variable in the STAC cohort in order to describe 
all cancer-exposed subjects by the “local”, “regional”, and “distant metastasis” no-
menclature. Three algorithms for this alignment were defined, as listed in Appendix 1.
The International Cancer Benchmark Partnership was established in order to compare 
cancer survival in six high-income countries, proposing an algorithm for conversion of 
TNM, FIGO and Duke’s cancer stages for colorectal, lung, breast, fallopian tube and 
ovary cancers.239 We adapted to this algorithm for relevant solid tumors. Types of can-
cers not covered by International Cancer Benchmark Partnership were mapped to the 
nomenclature “local”, “regional” and “distant metastasis” guided by recommendations 
from the American Cancer Society and National Cancer Institute (http://www.training.
seer.cancer.gov/ and http://www.cancer.org/cancer/index). However, the stages we 
refer to in the STAC cohort should not be interpreted as Surveillance, Epidemiology 
and End Results Summary Staging 2000 (SEER SS2000) stages,240 though they are 
comparable.
The Norwegian cancer stage data were mapped to the principal local, regional and di-
stant metastasis nomenclature by Algorithm 1 (Figure 2).
Algorithm 1DistantRegionalLocal
Figure 2. Norwegian cancer stages are classified by a Norwegian, principal system. 
 
Cancer stages of Danish patients diagnosed before 2004 are described by codes 0-9, A 
and B, and the code covers the principal Danish classification plus FIGO and Duke’s 
stages. Three variants of algorithm 2 was necessary since the same code for cancer 
stage could cover both FIGO, Duke and principal stages (Figure 3). Information on 
extent of cancer in cases after 2004 are coded in the TNM classification. Algorithm 3 
hierarchically mapped the variables M, N and T for each type of solid cancer (Figure 
3). For details of the algorithms, see Appendix 1.
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Figure 3. Danish cancer stages before and after 2004. ICBP, International Cancer Benchmark 
Partnership.239
SOURCES OF VTE INFORMATION
Information about VTE in study 4 and for the DCH subset of the STAC cohort (stu-
dy 1-3) was retrieved from the DNPR. In the DCH, all VTE events registered in the 
DNPR were validated by systematic review of medical journals and diagnostic tests. 
Only VTEs associated with typical symptoms and confirmed by diagnostic tests were 
included in DCH and hence in the STAC cohort. Additionally, fatal events identified 
in the Danish National death Registry confirmed by autopsy were included.41
In the Norwegian part of the STAC cohort, VTEs were identified in local registries at 
the sites of the HUNT and the Tromsø study, respectively, and subsequently valida-
ted. In the HUNT study, information about VTE was retrieved from local discharge 
registries and radiology procedure registries at the three hospitals in Nord-Trondelag. 
Symptomatic VTEs that was confirmed by imaging diagnostics and treated were in-
cluded in the HUNT study and thus in the STAC cohort.6 In the Tromsø study, VTEs 
were identified in the discharge diagnosis registry, radiology procedure registry and 
autopsy registry at the University Hospital of North Norway. VTE was confirmed if 
a symptomatic VTE diagnosed by a physician was confirmed by diagnostic imaging 
and treated with either anticoagulation or vascular surgery.241
In study 4, the ICD-10 codes for VTE (I26, I80.1-I80.9) were identified by direct lin-
kage to the CLL patients' civil personal registration numbers in the DNPR through 
Statistics Denmark. We subsequently excluded events solely coded in the emergency 
-2004 (except
gynecological and 
colorectal tumors)
National principal 
classification
Local Regional Distant
-2004 gynecological 
tumors
FIGO
mapped to principal 
classification as 
recommended by ICBP 
-2004 colorectal
tumors
Duke's classification
mapped to principal 
classification as 
recommended by ICBP 
After 2004
TNM
mapped to principal 
classification as 
recommended by ICBP 
/SEER SS200 
Algorithm 2 
Algorithm 3
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departments in case neither subsequent anticoagulation medicine was prescribed nor 
subsequent ward or ambulatory VTE coding was registered. 
Validation of VTE diagnoses in CLL patients
The positive predictive value and the sensitivity of VTE diagnosis among CLL patients 
was investigated by systematic review of the medical journals of all CLL patients tre-
ated at Aalborg University Hospital from 2008-2016. When clinical signs and diag-
nostic tests confirmed VTE, a registered VTE was considered valid, while VTE was 
ruled out in cases where accomplished diagnostic tests did not confirm the diagnosis. 
Medical records for the CLL patients without a registered VTE were systematically 
reviewed for unregistered valid VTEs. The positive predictive value was calculated 
as the proportion of validated VTE divided by the total number of VTEs registered in 
the DNPR. The sensitivity was calculated as the proportion of true positive VTEs re-
gistered in DNPR divided by the total number of validated VTE. 
ANTICOAGULATION MEDICATION
Information about anticoagulation in study 4 was retrieved from the Danish National 
Prescription Registry. Expenses to medicine is to some extent reimbursed in Denmark, 
and the Danish National Prescription Registry holds information about ATC codes 
of prescribed and purchased medicine, doses and package sizes.277 By use of the ci-
vil personal registration number, we identified which CLL patients were exposed to 
anticoagulation medication. In periods of hospitalization identified by linkage to the 
DNPR, we classified subjects exposed to anticoagulation in the immediate period be-
fore hospitalization as anticoagulated during hospitalization.
STATISTICS
STUDY 1
Study entry was the date of cancer diagnosis, and participants were followed until VTE, 
death, emigration or administrative censoring (i.e. last date of follow-up for VTE as 
described in Table 4). Incidence rates of VTE were calculated as number of VTEs per 
1000 PY for localized disease, regional spread and distant metastasis in ten distinct 
solid cancer types. To assess the impact of initial cancer stage on the risk of VTE on 
an absolute scale, incidence rate differences (IRD) were calculated. The cumulative 
incidence of VTE according to initial cancer stage was depicted treating death as com-
peting risk. Hazard ratios for VTE according to initial cancer stage were calculated in 
Cox proportional regression models with age and sex (in the gender unspecific cancer 
types) included as potential confounders.
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STUDY 2 AND 3
Matching
The cancer exposed subjects in study 2 and 3 were matched on age, gender and original 
cohort to five reference subjects within the STAC cohort at the date of hematological 
cancer diagnosis and the 2-year anniversary for the cancer diagnosis, respectively. 
The latter matching criteria was due to different end of follow-up for VTE in the three 
original cohorts (Table 4). References were free of VTE and cancer at the index date 
and their chances for selection as reference were proportional to their contribution to 
person-time at risk (i.e. incidence density sampling). By incidence density sampling 
of reference subjects unexposed at the index date, references are time-matched to ca-
ses and the incidence rate ratio can be directly estimated. In other words, a sample of 
person-time rather than a set of persons acts as references. 242,243
Follow-up and association measures
In study 2, subjects were followed from the hematological cancer diagnosis date/in-
dex date to VTE, death, emigration, last follow up for VTE and for reference subjects 
prospective first cancer diagnosis. IR and IRR of VTE were calculated for the total 
study period, for first year after study entry and for the period from one to five years 
after the study entry.
In study 3, subjects in the STAC cohort who had cancer after enrollment were matched 
to their reference subjects 730.50 days after the cancer diagnosis (if alive and free of 
VTE at this date). Follow-up commenced at this date and ended in case of VTE, end 
of follow-up for VTE, emigration or death. Additionally, for the reference subjects, 
a prospective first cancer diagnosis would terminate follow up, while a prospective 
second cancer diagnosis would for the cancer exposed subjects. In case the reference 
subjects got cancer after the index date and survived at least 730.50 days, they were 
included as cancer exposed subjects and 5 reference subjects were identified. IRs, 
IRDs and incidence rate ratios (IRR) were calculated for the entire follow-up (i.e. ≥ 2 
years after the cancer diagnosis) and three years after study entry (i.e. ≥ 5 years after 
the cancer diagnosis).
STUDY 4
In study 4, the subjects were followed from the date of their CLL diagnosis until 
VTE, death, emigration or last follow-up for VTE (December 31, 2015). Prospective 
cancer after the CLL diagnosis was treated as a time-varying exposure. Cumulative 
incidences of VTE were calculated according to CLL prognostic factors and second 
primary cancer after the CLL diagnosis in analysis treating death and death plus se-
cond primary cancer after the CLL diagnosis as competing risks in order to illustrate 
the possible overestimation of VTE if second primary cancer was ignored as compe-
ting risk. In analysis of mortality, VTE was treated as a time-varying exposure and 
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also as competing risk for death among those not (yet) exposed to VTE. The impact 
of patient specific and CLL prognostic factors on the risk of VTE was investigated in 
multivariate Cox models.
ETHICS
The DCH, HUNT and Tromsø studies were approved by the respective National scien-
tific ethics committees. Study participants gave informed written consent to linkage 
by their civil personal registration number to national health registries for research 
purposes.226-228 The Danish and Norwegian Data Protection Agencies approved mer-
ging of the three original cohorts in the STAC cohort, further approval was hence not 
required for study 1, 2 and 3.66 The use and linkage of data in study 4 was approved 
by the Danish Data Protection Agency (2008-58-0028, internal reference 2017-93). 
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RESULTS
STUDY 1: IMPACT OF INITIAL CANCER STAGE ON THE 
INCIDENCE OF VTE
Previous studies where the impact of cancer stage on the risk of VTE was investigated 
either combined several cancer types or investigated a single cancer type leaving little 
option to evaluate if the effect of cancer stage was similar in different cancer types. In 
study 1244, the impact of initial cancer stage in different cancer types was investigated 
by comparing the risk of VTE in localized cancer with regional spread and distant me-
tastasis in ten distinct cancer types based on data from the STAC cohort.
In total 10 583 participants in the STAC cohort were diagnosed with either lung, co-
lorectal, upper gastrointestinal, pancreatic, breast, prostate, bladder, kidney, uterine or 
ovarian cancer. The cancer was localized at the time of diagnosis for 38% of the pa-
tients, for 30% it was regionally spread, 17% had distant metastasis while in 14% the 
initial cancer stage was actively coded “unknown” in the respective National Cancer 
Registries. Three hundred and thirty-five VTEs occurred in the study period, 54% 
within the first year after the cancer diagnosis.
The impact of initial cancer stage on the risk of VTE varied considerably by cancer 
type and time since cancer diagnosis. The IRD of VTE in distant metastatic cancer was 
larger than zero compared with localized disease in most cancer types in the first year 
after the cancer diagnosis (i.e. the IR of VTE was higher in distant metastasis compared 
with localized disease), but varied from 3.7 (95% CI, -7.0 to 15.2) more VTEs per 1000 
PY in distant metastasis compared with localized disease in prostate cancer to 187.0 
(95% CI -6.7 to 380.8) in pancreatic cancer. (Figure 4) The IRD of VTE in regional 
spread lung, colorectal, upper gastrointestinal, pancreatic, uterine and ovarian cancer 
was also larger than zero compared with localized disease in the first year after the 
cancer diagnosis, highest in uterine cancer (IRD 37.6, 95% CI -23.7 to 99.0). In breast 
however, the IRD was close to zero (i.e. the IR of VTE in regional spread and localized 
disease were similar). Most of the VTEs that contributed to the IRDs of VTE in regio-
nal spread and distant metastasis compared with localized disease in the 5-year period 
after the cancer diagnosis occurred during the first year after the cancer diagnosis.244
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Figure 4. Incidence rates of VTE per 1000 PY according to initial cancer stage for ten cancer 
types 0-1 year after the cancer diagnosis.
Age and gender adjusted HR for VTE within the first year after cancer diagnosis in 
distant metastasis varied considerably by cancer type, lowest in prostate cancer (HR 
1.5, 95% CI 0.3-8.3) and highest in colorectal cancer (HR 16.5, 95% CI 3.6 -74.6) 
(Table 5). The HRs of VTE were lower in general in regional spread cancer, lowest 
in breast cancer (HR 0.9, 95% CI, 0.3-3.1) and highest in colorectal cancer (HR 7.1, 
95% CI 1.7-30.1).244  
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STUDY 2: EPIDEMIOLOGY OF VTE IN HEMATOLOGICAL 
CANCERS
Previous studies concerning VTE in hematological cancer covered either several types 
combined in one group or one or a few similar types of hematological cancer. In or-
der to compare the associations with VTE for various types of hematological cancer, 
patients with six distinct types of hematological cancer were matched on age, sex and 
original cohort to reference subjects free of cancer in the STAC cohort in study 2.245
Selected references could get solid or hematological cancer along the study period, in 
which case they were either censored (n= 395) or shifted to contribute with person-time 
at risk in the hematological cancer exposed group (n=26) at time of cancer diagnosis.
During follow up, 30 VTEs were observed among 838 subjects exposed to hematolo-
gical cancer in total. Twenty-one VTEs occurred among the 4190 references. In CLL, 
myeloma and aggressive lymphoma the IRs of VTE were considerably higher than in 
 HR (95% CI) 
0-1 year 
HR (95% CI) 
0-5 years 
Regional spread vs. localized 
Lung 2.8 (0.9 - 8.3) 2.6 (1.1 - 6.2) 
Colorectal 7.1 (1.7 - 30.1) 4.4 (1.8 - 10.4) 
Upper GI 2.5 (0.3 - 21.2) 0.9 (0.2 - 4.0) 
Pancreatic 1.4 (0.2 - 11.2) 1.7 (0.2 - 13.4) 
Breast 0.9 (0.2 - 3.1) 1.4 (0.6 - 3.2) 
Prostate - 1.0 (0.3 - 3.6) 
Bladder - 2.0 (0.5 - 7.3) 
Uterus 3.3 (0.7 – 15.1) 4.9 (1.4 - 17.2) 
Ovary - 1.5 (0.1 - 25.2) 
Distant metastasis vs. localized 
Lung 4.8 (1.7 - 13.7) 4.1 (1.8 - 9.4) 
Colorectal 16.5 (3.6 – 74.6) 10.5 (4.0 - 27.8) 
Upper GI 9.1 (1.1 - 78.8) 4.0 (0.9 - 17.3) 
Pancreatic 4.3 (0.5 - 35.7) 4.9 (0.6 - 40.6) 
Breast 5.4 (1.1 - 27.1) 9.9 (3.4 - 29.0) 
Prostate 1.5 (0.3 - 8.3) 2.1 (0.9 - 5.0) 
Bladder 7.6 (1.3 – 46.0) 14.9 (2.5 - 90.0) 
Kidney 1.7 (0.4 - 7.4) 3.1 (0.9 - 10.9) 
Uterus - 6.5 (0.7 - 57.9) 
Ovary - 4.5 (0.5 - 37.5) 
 
Table 5. Hazard ratios of VTE for regional spread cancer and distant metastasis compared with 
localized disease. Modified from 244.
VENOUS THROMBOEMBOLISM IN SOLID AND HEMATOLOGICAL CANCERS
56
reference subjects. In aggressive lymphomas the IR was however mainly higher in the 
first year after the diagnosis. The indolent lymphomas contributed to similar amount 
of person time at risk of VTE as the CLL patients. Despite this, only one VTE was 
observed in indolent lymphoma, resulting in an IR of VTE not significantly different 
from the reference subjects (Figure 5).
Figure 5. Incidence rates of VTE for by type of hematological cancer and associated 95% con-
fidence intervals 0-1 year after the cancer diagnosis and 1-5 years after the cancer diagnosis.
STUDY 3: LONG-TERM INCIDENCE OF VTE IN CANCER
The risk of VTE in close temporal association with the cancer diagnosis has been exten-
sively studied while the risk of VTE after possible attenuation of effects from cancer 
and associated treatments is sparsely investigated. In study 3,246 we compared the inci-
dences of VTE in cancer survivors (i.e. subjects alive and free of VTE two years after 
a cancer diagnosis) and reference subjects free of VTE and cancer at the index date 
based on data from the STAC cohort.
In total 7645 subjects were alive and free of VTE two years after their cancer diagnosis, 
where they entered this study. In total 110 VTEs occurred among the cancer exposed 
subjects, 44 of them were diagnosed later than five years after the cancer diagnosis. 
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Cancer exposed subjects had a higher IR of VTE than references, both in the entire 
study period and also when restricted to the VTEs that occurred later than five years 
after the cancer diagnosis. This was mainly caused by a sustained higher IR of VTE 
in the hematological cancers compared with reference subjects. For survivors of solid 
cancer types as prostate and colorectal cancer, the risk of VTE resembled the referen-
ces subjects (Figure 6). In the solid cancer types, initial distant metastasis was associ-
ated with a 6-fold higher IR of VTE more than two years after the cancer diagnosis.246
Figure 6. Incidence rates of VTE in cancer survivors and reference subjects by successive time 
from cancer diagnosis.
STUDY 4: VTE IN CHRONIC LYMPHOCYTIC LEUKEMIA
The etiology of VTE in CLL patients has not been thoroughly investigated, however 
a few studies indicated that the risk of VTE could be noticeably higher than in the 
background population. Some studies indicated that CLL patients had a considerable 
risk of second primary cancers, but it was not investigated if this was associated with 
the risk of VTE. In study 4,247 we investigated the epidemiology of VTE in a Danish, 
national CLL cohort diagnosed in 2008-2015. Information concerning second primary 
cancers was included. The VTE diagnoses were validated in a local dataset covering 
10% of the total study population.  
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VALIDITY OF THE VTE DIAGNOSES IN CLL PATIENTS
Medical journals from 469 CLL patients were systematically reviewed in the valida-
tion study. Thirty-two VTEs were coded in the DNPR. During the validation process, 
six additional VTEs were identified. Fifteen percent of the registered VTEs were not 
confirmed after review of medical journals and diagnostic tests. In five cases, VTE was 
classified as probable and in 28 cases, VTEs were confirmed. Fourteen were pulmo-
nary embolisms and 22 deep vein thromboses, and in three of the cases, the deep vein 
thrombosis and pulmonary embolism were concurrent. Four (12.1%) of the validated 
VTEs were asymptomatic (i.e. diagnosed coincidentally because a CT scan was per-
formed), three of which were registered in the DNPR. The positive predictive value of 
VTE diagnosis codes in DNPR was 84.4 % (95% CI, 67.2 - 97.4) while the sensitivity 
was 81.8% (95% CI, 64.5 - 93.0). In order to assess if a diagnosis of CLL influenced 
the validity of VTE diagnoses, we calculated the positive predictive value and sensi-
tivity of VTEs that occurred after the CLL diagnosis. Twenty-two of the 33 validated 
VTEs occurred after the CLL diagnosis, the positive predictive value was 84.2% (95% 
CI, 60.4 – 96.6) and the sensitivity was 76.2% (95% CI, 52.8 - 91.8).
VTE IN THE DANISH CLL PATIENTS
We followed 3609 CLL patients for a median of 2.6 years. In total, 102 of the CLL 
patients had a VTE diagnosis registered after the CLL diagnosis. For ten of these, 
however, no subsequent ambulatory or ward coding of VTE was done, and no antico-
agulation treatment was prescribed. These ten events were not included in the analysis 
due to questionable validity of the diagnosis. A considerable proportion of the CLL 
patients died during follow-up (20%) and 13% were diagnosed with a second primary 
cancer after the CLL diagnosis.
Sixteen of the 92 VTEs were diagnosed at or after a diagnosis of second primary 
cancer, and six of the 92 VTEs were diagnosed before a diagnosis of second primary 
cancer. Fifteen of the 92 CLL patients with VTE after the CLL diagnosis had a history 
of VTE. Three of the 15 VTEs preceding the CLL diagnosis could be the same as the 
one after the diagnosis of CLL because the time interval between the first registered 
VTE and the second was less than 30 days. 
Exposure to VTE before the CLL diagnosis was associated with the highest risk of VTE 
followed by exposure to second primary cancer. A second primary cancer among CLL 
patients exposed to VTE before the CLL confounded this association, HR of VTE in 
previous VTE compared with no previous VTE however remained the highest obser-
ved in the study (Table 6). 
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Table 6. Hazard ratios of VTE by patients related factors and CLL specific markers. Modified 
from 247.
In interaction analysis, we found markedly higher effect of previous VTE on the risk of 
VTE after the CLL diagnosis in age groups >60 - ≤70 years, >70 - ≤80 and >80 years 
compared with ≤ 60 years. In analysis of previous VTE stratified by age, HR for VTE 
after CLL was 0.83 (0.10 – 6.69) in subjects ≤65 years of age exposed to previous VTE 
compared with subjects free of previous VTE, while for those > 65 years the HR was 
6.34 ( 3.37 – 11.91) if exposed to previous VTE (Table 7). In other words, age was not 
strongly related to the risk of VTE unless exposed to VTE before the CLL diagnosis.
 HR, crude (95% CI) HR, model 1 (95% CI) HR, model 2 (95% CI) 
Patient related factors    
  Previous VTE    
        No Reference Reference Reference 
       Yes 5.79 (3.27 - 10.26) 5.29 (2.93-9.57) 5.09 (2.82 - 9.17) 
 Second primary cancer     
       No Reference Reference NA 
       Yes 3.72 (2.15 – 6.34) 3.65 (2.10-6.35) NA 
  Anticoagulation*     
       No Reference Reference Reference 
       Yes 1.35 (0.65 – 2.08) 0.92 (0.43 – 1.95) 0.92 (0.44 – 1.95) 
CLL prognostic markers    
  IgHV mutational status    
       Mutated Reference Reference Reference 
       Unmutated 1.63 (1.06 - 2.54) 1.65 (1.07-2.57) 1.63 (1.05 - 2.53) 
       Not assessed ND ND ND 
  FISH     
       Deletion 13q14 Reference Reference Reference 
       Normal FISH 1.15 (0.61 - 2.14) 1.13 (0.60-2.13) 1.10 (0.59 - 2.06) 
       Trisomi 12 2.69 (1.42 - 5.10) 2.44 (1.26-4.72) 2.37 (1.23 - 4.59) 
       Deletion 11q / 17p 3.09 (1.67 - 5.72) 2.63 (1.28-5.40) 2.44 (1.20 - 4.99) 
β2-microglobulin, mg/L    
       < 4 Reference Reference Reference 
       ≥ 4 2.60 (1.55 - 4.37) 1.88 (1.08-3.27) 1.97 (1.14 - 3.41) 
       Not assessed ND ND ND 
Model 1: Adjusted for anti-coagulation treatment, WHO-PF, previous VTE, sex and age 
Model 2: Adjusted for anti-coagulation treatment, WHO-PF, previous VTE, sex age and second 
primary cancer 
*Adjusted for previous VTE, age and sex in model 1 and previous VTE, age, sex and second 
primary cancer in model 2 
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Table 7. Age stratified analysis of the effect of previous VTE on VTE after the CLL diagnosis.
Regarding CLL prognostic markers, the risk of VTE was highest in CLL patients with 
β2-microglobulin levels above 4 mg/L and unmutated IgHV genes (Figure 7). These 
associations were not confounded by second primary cancer. (Table 6). Trisomy 12, 
Del11q and del17p were also correlated to the risk of VTE, while normal FISH did 
not increase the risk of VTE significantly compared with Del 13, which is a favorable 
prognostic marker in CLL248 (Table 6, Figure 7).
 PY IR (95% CI) HR, crude (95% CI) HR, adjusted* (95% CI) 
≤ 65 years, previous VTE     
  No  4 257 6.3 (4.3 – 9.2) Reference Reference 
  Yes 71 14.0 (2.0 – 99.3) 2.03 (0.27 – 14.95) 0.97 (0.12 – 7.88) 
> 65 years, previous VTE     
  No 6 637 7.5 (5.7 – 9.9) Reference Reference 
  Yes 234 59.7 (35.4 – 100.9) 6.62 (3.59 – 12.20) 6.68 (3.57 – 12.49) 
*Adjusted for anti-coagulation treatment, WHO-PF, previous VTE, sex and second primary cancer. 
 
Figure 7. Cumulative incidences of VTE according to CLL prognostic factors, modified from 247. 
 
Exposure to CLL treatment increased the risk of VTE (HR 2.40, 95% CI, 0.91-6.30). 
Several types of chemotherapy and immunotherapy and combinations hereof were 
represented among the CLL patients who were diagnosed with VTE during CLL 
treatment. 
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The mortality of CLL patients with VTE was marginally higher than in CLL patients 
without VTE after the CLL diagnosis (Figure 8). WHO performance status, age, sex, 
CLL risk profile and second primary cancer did not influence this association (cru-
de and adjusted HRs 2.20 [95% CI, 1.43 – 3.37] and 2.13 [95% CI, 1.39 – 3.27], 
respectively).
Figure 8. Cumulative mortality and associated 95% confidence intervals of CLL patients accor-
ding to VTE after the CLL diagnosis. Modified from 247.
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GENERAL DISCUSSION
 
Research aims to describe the real world by models applied to some sample, i.e. a small 
part of the real world. This will, however, always result in approximations for several 
reasons. First and foremost, the generalizability of observations in the sample of the 
real world depends on the degree of systematic errors within the sample. Furthermore, 
the applied models will always be approximations of the real world as they are too 
“small” to contain all aspects of the real world in the same way that a toy-car is too 
small to contain all the functional parts that make a real car. 
The studies within this thesis aimed at describing several aspects of the epidemiology 
of cancer-associated VTE based on register data. None of the data sources were desig-
ned specifically for these studies. However, all data have been prospectively collec-
ted, which entail benefits as well as limitations discussed in this chapter. Furthermore, 
medical statistics continuously evolves and facilitates statistical models that bring 
estimates to a new level of complexity. The statistical methods used in the presented 
studies will be discussed along with new methods for data quality improvement and 
models for effect estimation.
METHODOLOGICAL CONSIDERATIONS
PRECISION AND POWER
Random error will always be some part of the explanation of estimates based on data 
from a sample. The extent of random error depends mainly on the sample size (i.e. 
number of observations) and precision of measurements in the sample. The width of 
confidence intervals of an estimate indicates its precision, where the true value of the 
investigated parameter will be inside the margins of the 95% confidence intervals 95 
times if the study was repeated 100 times. Estimates from repeated studies will more 
frequently be close to the center of the confidence interval. The effect estimates in stu-
dy 1-3 lacked precision as the sample size was small when divided into cancer types 
and stages. Hence, there was a lower probability of effect estimates being statistically 
significant if a true association actually existed (i.e. lack of power).249 The results from 
these studies nevertheless indicate associations, but what the studies lack in precision 
and power, they do to some degree gain in validity, which is discussed below.
BIASES
Systematic errors in data can introduce biased results by three overall mechanisms. In 
case of confounding, measures of the association between exposure and outcome can 
become biased due to influence from a factor (confounder) that is both predictive of 
the outcome and also associated with the exposure.242 Confounders are inherent in the 
real world population as well as in the studied sample, and thus a condition that needs 
attention in all study designs. Matching on confounder variables is the most common 
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method to control the effect of confounders in the study design phase. Additional met-
hods can estimate the impact of the confounders on the effect estimate in the analysis 
phase, most simply by stratifying on the confounding variable or by inclusion of con-
founders in regression models.
Selection bias arises in the process of selection of the study sample if recruited and/or 
retained study subjects systematically differs from the real world.242 This type of bias 
is not a problem in cohort studies with complete follow-up, as for instance the subjects 
in study 4, but might be present in the original studies in the STAC cohort.66 All adult 
inhabitants in the geographical areas covered by the three cohorts were invited to par-
ticipate. Attendance rates varied from 35% in the DCH study to 77% in the Tromsø 
study. This selection bias can affect the external validity, as participants in health sur-
veys tend to be healthier and have higher socio-economic status than non-attendants.250 
Information bias arise after selection of the study sample because of systematic errors 
with respect to the classification of the study subjects’ exposure, outcome and confoun-
der variables.242 Information bias is diminished by use of high quality register data in 
study 1-4, and, additionally, use of validated outcomes in study 1-3. Ascertainment 
bias or medical surveillance bias is a type of information bias caused by more frequent 
medical examinations of exposed than unexposed subjects leading to systematically 
higher proportions of detected outcome (VTE) among exposed subjects. However, 
this bias is probably minor in studies 1-3 because solely symptomatic VTEs were in-
cluded. Different methods for assessment of and handling biases are discussed below.
DATA QUALITY
Measures of data quality
Danish health care data was used in all four studies where cancer was the main exposure 
and VTE was the main outcome. Danish residents have income-independent access to 
universal tax-funded health care. Linkage of data from various registries is possible by 
use of the civil personal registration number providing extensive long- term tracking 
of individuals and cradle-to-grave follow-up at a national level. However, despite this 
ideal constellation for researchers within the field of clinical epidemiology, possible 
misclassification should be taken into consideration when findings based on health 
care data are interpreted. Human error does occasionally result in misclassification; 
non-diseased subjects receiving a diagnosis code classifying them as diseased, while in 
other occasions diseased patients are not registered and thus classified as non-diseased. 
The validity of the main exposure in studies 1-3 has been evaluated by several met-
hods encompassing the number of data sources per case, the proportion of cases only 
verified from death certificates, and the number of cases with unknown cancer type but 
microscopically verified cancer diagnoses are warranted. The proportion of microsco-
pically verified diagnoses in Danish Cancer Registry has not been evaluated since 
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1992, where 93% were confirmed.238 Study 1 – 3 additionally included information 
from the Norwegian Cancer Registry, where 94% of cancers registered in 2001-2005 
were microscopically verified.235
For the main outcome in all four studies, the optimal estimation of misclassification 
of diagnoses would be assessment of sensitivity and specificity, however calculation 
of the positive predictive value and assessment of data completeness are more feasible 
measures of data quality, as described below.
In Table 8, A denotes diseased subjects with a (VTE) diagnosis in the register (true 
positive), B denotes subjects registered with disease but in reality non-diseased (false 
positive), C denotes diseased subjects without a registered diagnosis (false negative) 
and D denotes non-diseased, unregistered subjects (true negative).
Table 8. Validity of data, modified from Szklo et al.242
The validity of a diagnosis is optimally characterized by its sensitivity (the proportion 
of diseased subjects who are registered, i.e. A/A+C) and specificity (the proportion of 
non-diseased not registered with the disease, i.e. D/B+D). 
The sensitivity and specificity of registered diagnoses can be measured by systematic 
review of medical journals of a sample of both diseased and non-diseased individuals 
in a cohort, as described in the validation of VTE diagnoses codes in study 4 and simil-
arly in Danish prostate cancer patients.251 The sensitivity and specificity (of a diagnosis 
code) depend on the “true diseased” (A+C) and “true non-diseased” (B+D), and these 
indices of validity are hence theoretically not related to the disease prevalence.242 The 
specificity will be close to 1 for relatively rare diseases in a large population, while 
the data completeness e.g. in a local discharge registry is an estimate for the sensitivity 
when evaluated by comparing data from “the gold standard registry”: 252 
In the register The truth   
 Diseased Non-diseased  
Diseased A B A+B 
Non-diseased C D C+D 
 A+C B+D total 
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The positive predictive value (proportion of true positive among all subjects registered with 
the disease, A/A+B) and the data completeness can be estimated by comparison of data from 
two registries or by review of medical journals from patients registered with the disease 
(A+B).41,251,253,254 Both of these methods are more feasible than direct measurement of 
specificity and sensitivity, however, the two methods hinder direct comparison of measures 
of data validity between studies.  
All potential VTEs included in the DCH, Tromsø and HUNT studies and hence in the STAC 
cohort were identified by linkage to local (Tromsø and HUNT) or national registries (DCH) 
followed by objective confirmation by review of medical journals. The positive predictive 
value of a registered VTE was not reported for the Tromsø and HUNT studies.6,241 However, 
740 out of 1526 (48%) possible VTEs identified in the discharge registry were objectively 
confirmed in HUNT study.6  For participants in the DCH, the positive predictive value of a 
VTE discharge diagnosis in the DNPR was 75% if restricted to wards, while for discharge 
diagnoses from emergency departments it was 31%.41 Thus, the inclusion of solely 
objectively confirmed VTE events in the STAC cohort is fundamental for its’ high quality of 
VTE data. 
In study 4, the VTE events among CLL patients were identified in the DNPR, follow-up was 
from 2008 -2015 which was after last follow-up for the VTE in DCH.41 The validity of VTE 
data in the total local CLL population was assessed in forms of systematic review allowing 
for estimation of sensitivity and specificity of VTE diagnosis in the DNPR. For VTEs that 
occurred after a CLL diagnosis, the positive predictive value was 84.2%, while sensitivity 
and specificity were 76.2% and 99.3%, respectively. The positive predictive value was 
similar in a recent Danish study that assessed the validity of VTE diagnoses by review of 
medical journals of a sample of 100 VTE patients (88%).254  The sensitivity of VTE diagnosis 
codes was assessed among Danish prostate cancer patients (1995-2012) by review of medical 
journal of all subjects with a VTE diagnosis in the DNPR (n=120) plus review of medical 
journals in a sample of prostate cancer patients with no VTE diagnosis code in the DNPR 
(n=120).251 The sensitivity of VTE diagnosis codes was higher compared with our study 
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The positive predictive value (proportion of true positive among all subjects registered 
with the disease, A/A+B) and the data completeness can be estimated by comparison 
of data from two registries or by review of medical journals from patients registered 
with the disease (A+B).41,251,253,254 Both of these methods are more feasible than direct 
measurement of specificity and sensitivity, however, the two methods hinder direct 
comparison of measures of data validity between studies. 
All potential VTEs included in the DCH, Tromsø and HUNT studies and hence in 
the STAC cohort were identified by linkage to local (Tromsø and HUNT) or national 
registries (DCH) followed by objective confirmation by review of medical journals. 
The positive predictive value of a registered VTE was not reported for the Tromsø 
and HUNT studies.6,241 However, 740 out of 1526 (48%) possible VTEs identified in 
the discharge registry were objectively confirmed in HUNT study.6  For participants 
in the DCH, the positive predictive value of a VTE discharge diagnosis in the DNPR 
was 75% if restricted to wards, while for discharge diagnoses from emergency depart-
ments it was 31%.41 Thus, the inclusion of solely objectively confirmed VTE events in 
the STAC cohort is fundamental for its high quality of VTE data.
In study 4, the VTE events among CLL patients were identified in the DNPR, follow-up 
was from 2008 -2015, which was after last follow-up for the VTE in DCH.41 The vali-
dity of VTE data in the total local CLL population was assessed in forms of systematic 
review allowing for estimation of sensitivity and specificity of VTE diagnosis in the 
DNPR.247 For VTEs that occurred after a CLL diagnosis, the positive predictive value 
was 84.2%, while sensitivity and specificity were 76.2% and 99.3%, respectively. The 
positive predictive value was similar in a recent Danish study that assessed the validi-
ty of VTE diagnoses by review of medical journals of a sample of 100 VTE patients 
(88%).254  The sensitivity of VTE diagnosis codes was assessed among Danish prostate 
cancer patients (1995-2012) by review of medical journals of all subjects with a VTE 
diagnosis in the DNPR (n=120) plus review of medical journals in a sample of prostate 
cancer patients with no VTE diagnosis code in the DNPR (n=120).251 The sensitivity 
of VTE diagnosis codes was higher compared with our study (98% vs. 76.2%), while 
corresponding positive predictive value was similar to what we observed (86.1% vs. 
84.2%).251 As the assessment methods differed, the estimates from study 4 are, how-
ever, not directly comparable to the estimates from Drljevic et al.251  Nevertheless, it 
indicates that the true validity behind apparent similar positive predictive values might 
differ considerably. For practical reasons, however, the positive predictive value will 
probably remain the preferred measure of register data validity.
Missing data
Missing data is a problem, although variable in all data sources. Estimates based on 
datasets with missing data can be biased if the reason for missing is associated with 
observed information (i.e. missing at random) or non-observed information (i.e. mis-
sing not at random). Estimates will not be biased if data are missing completely at 
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random, which is however, unusual. Several methods for dealing with missing data 
exists. They are developed in order to maintain the study sample size and thus statisti-
cal power and precision, and to assess the impact of the missing data on the estimates. 
In single value imputation, the missing values are replaced with one value. The single 
value can be obtained by replacing the missing value with the mean of the observed 
values, or by the last measured value. Another way to handle missing data is worst and 
best-case sensitivity analysis where the missing values are replaced by the extreme 
values. These single value methods provide one full copy of the dataset and hereby 
no consideration of the uncertainty the imputed value carry forward into the analysis. 
Possibly, these methods provide significant associations because standard errors will 
be falsely narrow. Moreover, results from this from of dataset is not really useful in 
case the estimate differ from the complete case analysis. Alternatively, missing data 
can be handled by use of other variables in the dataset. Multiple imputation is the most 
recognized method within this category. Multiple imputation allows for the inherent 
uncertainty of missing/imputed values by creation of several plausible datasets by use 
of predefined variables in the dataset and finally combining the results from all of these 
data sets taking uncertainty of the imputed datasets into accunt.255,256  
In study 1, less than 1% of cancer stages were actually missing, i.e. had no value in the 
variables for cancer stages in the registries, while 14% were actively coded “unknown” 
stage. A code for “unknown stage” was however not per se equal to “unknown”. For 
some subjects - especially early in the study period - it could have meant “missing”.235 
The authors of a recent study on Norwegian breast cancer patients chose to treat the 
patients with actively coded “unknown” cancer stage as missing data.257 The impact of 
the actively coded “unknown” cancer stages was assessed both in worst and best-case 
sensitivity analyses, and by multiple imputation of the missing values based on age, 
survival and calendar period of the cancer diagnosis. The estimates did however not 
change markedly in either of the datasets with replacement of missing data, hence there 
is no reason to believe that missing data did bias the estimates in the initial comple-
te case analysis even though data were not missing completely at random. This lead 
to post-publication speculations about use of multiple imputation in study 1. Table 
9 shows that actively coded “unknown” cancer stage is more frequent in the earliest 
calendar period and among subjects that were older at the time of cancer diagnosis. 
Furthermore, the distribution varied by cancer type.244 The missing data were associa-
ted with observed information and multiple imputation would thus have been an option 
however unlikely to have affected our results. 
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Table 9. Missing and actively coded “unknown” cancer stage in study 1.
 Localized, regional or 
distant metastasis 
Actively coded 
“unknown” cancer stage 
Missing value in 
stage variable 
Age groups 
20-62 89.5% 10.4% 0.1% 
62-68 88.7% 11.2% 0.2% 
68-74 84.7% 15.2% 0.1% 
74-99 75.8% 24.2% 0.0% 
Calendar period 
1993-2001 82.4% 17.4% 0.1% 
2001-2005 83.5% 16.3% 0.2% 
2005-2008 86.0% 13.9% 0.1% 
2008-2011 88.0% 12.0% 0.0% 
 
In study 4, very few data were actually missing. Binet stage was the only complete 
prognostic variable while 14%-25% of the other CLL prognostic markers had a value 
for “Not assessed” in the dataset. The CLL patients with “not assessed” values were 
typically older than 60 years of age at the CLL diagnosis and 75% had Binet stage A 
disease.244 Furthermore, if one prognostic variable was not assessed, there was a higher 
proportion of other prognostic variables being unassessed (Table 10). This means that 
for the most optimal variables for multiple imputation, data would be missing as well. 
 
Table 10. Proportion of “not assessed” IgHV values in study 4 (n=806).
 Normal FISH Abnormal FISH  FISH “not assessed” 
β2 –microglobulin 
>  4 mg/L 15 (1.2%) 37 (4.6%) 39 (4.8%) 
< 4mg/L 68 (8.4%) 171 (21.2%) 172 (21.3%) 
Not assessed 44 (5.5%) 113 (14.0%) 147 (18.2%) 
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The actual pattern of missing data is as important as the proportion of missing valu-
es.258 Missing values in prognostic variables in study 4 was associated with being older 
and having a normal bone marrow function. This pattern indicates that estimates in a 
sensitivity analysis in a best-case scenario would not change markedly.
SELECTION OF REFERENCE SUBJECTS IN MATCHED 
STUDIES 
In principle, two different methods for sampling of controls within a defined cohort 
gives rise to two different study designs, or types of nested case-controls designs: By 
incidence density sampling of reference subjects unexposed at the index date, inci-
dence rate ratio can be directly estimated. If, on the other hand, reference subjects are 
sampled from the total cohort including exposed subjects all with the same chance 
of being selected as reference subjects, the risk ratio can be directly estimated.242,243 
Person time-data is however not used in the latter design, but it enables use of the same 
control group for several outcomes. Since we were interested in using the available 
person-time data in the STAC cohort in study 2 and 3, we chose the incidence density 
sampling method for selection of references. 
SHARED FRAILTY WITHIN MATCHES
Latent effects common within the group of the case and its selected reference subje-
cts could lead to shared proneness (frailty) for VTE within matches and thereby lead 
to biased effect estimates.278 Shared frailty models could have been included in study 
2 and 3. However, adjustment for shared frailty was done in a preliminary dataset in 
study 2, where shared frailty within matches did not change estimates markedly (crude 
HR for VTE in hematological cancer compared with reference subjects: 5.05, 95% CI 
2.94-8.67, HR adjusted for shared frailty: 5.40, 95% CI 3.12-9.31). In study 2, crude 
incidence rate ratios were reported, no further adjustment for age, gender or shared 
frailty was done in the final study. Due to few events, a regression model would be 
restricted to include very few parameters,259 in this regard age and sex could probably 
not have been ignored, as discussed below.
ADJUSTMENT FOR MATCHING VARIABLES
Study 2 and 3 were matched cohort studies, where matching variables were age, sex 
and original cohort. In this study design, the matching variables can be ignored as long 
as no adjustment for other confounders take place. However, if regression models are 
constructed, they should include the matching variables along with the non-matching 
confounders of interest.260,261 Since reasonable regression models should include at least 
age and sex in addition to other possible confounders, we chose not to do any regressi-
on analysis because they would be too complex for the sample size in study 2. In study 
3, we used Poisson regression to adjust for ageing since cancer diagnosis and sex.246 
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CAUSALITY 
While appraisal of associations observed in an individual study is based on evaluation 
of random and systematic errors in the particular study as described above, inferen-
ce of causality is based on all available evidence.242,249 Bradford Hill proposed nine 
criteria for evaluation of causality, however not all are relevant or applicable for the 
studies in this thesis.262 First of all, causality necessitate temporality; the exposure 
must precede the outcome. Second, strong associations are more likely causal as the 
alternative explanations for the association are less likely. Relative risks above 3 are 
suggested to characterize a strong association, but relative risks closer to 1.0 does not 
preclude causality.263 Third, consistent findings of the association in other studies with 
different study designs and samples indicate a causal association. Last, a biological 
gradient (i.e. dose-response relationship) and biological plausibility also indicates that 
an association is causal.
A single exposure seldomly causes the outcome alone. Most often, the exposure is a 
part of a combination of causes sufficient for the outcome (Figure 9).264  
Figure 9. Three sufficient causes of an outcome. Modified figure from Rothman264.
ASSOCIATION MEASURES 
Estimates of occurrence and effect (i.e. strength of an association) would ideally be 
calculated by comparing the same person with itself in exposed and unexposed condi-
tion without time lag. This is obviously a hypothetical situation and the best approxi-
mation to this utopian ideal is to design scientific studies to resemble. Three general 
principles to bear in mind in the analysis phase of studies were recently formulated.265 
 
1: Do not condition on the future.
2: Do not regard individuals at risk after they have died.
3: Stick to this world.
Sufficient cause 1 Sufficient cause 2 Sufficient cause 3
B
H
E
G
A
B
E
F
A
B
CD
A
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Although simple, these principles are nonetheless relevant in the following discussion 
of association measures.
Occurrence measures
The development of VTE over time (i.e. incidence) was investigated in all four studi-
es in this thesis by use of two measures of occurrence: incidence rates and cumulative 
incidence (proportion). Both measures have the number of new events in the sample in 
the numerator. The denominator of incidence rates is the person-time at risk of VTE, 
whereas in the cumulative incidence the denominator is number of study subjects at 
risk at the beginning of the time unit.268 For estimated cumulative incidences to be ge-
neralizable to the real population, one basic assumption needs to be met: The sample 
must be representative for the population at any given time in the study (not restricted to 
study entry), hence those who leave the study sample due to censoring should be repre-
sentative of the study population at any given time. This is referred to as independent 
right censoring or non-informative censoring.279 In our studies, cancer patients who die 
(and therefore become censored) are obviously not comparable to subjects still contri-
buting to person-time at risk for VTE in the study as dead precludes the occurrence of 
VTE. In study 4, we additionally noted that CLL patients who became exposed to an 
additional cancer in the study period had a fundamentally altered probability of VTE 
occurrence. This was handled by treating death and in study 4 also second primary 
cancer as competing risks in calculation of the cumulative incidence of VTE by use of 
the Aalen-Johansen estimator.266 This method differs from the traditional Kaplan-Meier 
method by taking into account the risk of VTE and the risk of death and, additionally, 
in study 4, the risk of second primary cancer, while the Kaplan-Meier estimate would 
describe the risk of VTE assuming that patients who had a second primary cancer had 
the same risk of VTE as those still in the study (i.e. violation of the assumption of in-
dependent right censoring). Furthermore, the Kaplan-Meier estimate treating all other 
events as censored assumes that censored subjects could later experience a VTE (i.e. 
those who die can experience a VTE) and estimates the occurrence of VTE as if VTE 
was the only possible outcome.92 Hereby, the Kaplan-Meier estimator regards indivi-
duals at risk after they died and does not stick to this world as alternative outcomes 
are obviously possible.    
We used the cumulative incidences to depict the time-dependency of VTE risks from 
the date of cancer diagnosis (study 1,2 and 4) and the two-year anniversary of cancer 
diagnosis (study 3). Additionally, we could have used the cumulative incidences as 
measures of occurrence of VTE by time since cancer diagnosis, if we had started the 
study entry with successive time since cancer diagnosis.267 Instead, we calculated IRs 
of VTE in different time intervals since cancer diagnosis. In calculation of IRs, study 
subjects contribute to person-time at risk from study entry until VTE, administrative 
censoring or competing events.242 Hence, when study subjects are no longer at risk of 
VTE, they do not contribute to person-time at risk meaning that the IR does stick to 
the real world and does not regard subjects at risk after they are dead.  The precision of 
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estimates of IR depends on the number of events and not sample size (i.e. person-time 
at risk),268 and the associated confidence intervals were thus generally broad in study 
1 and 2 despite considerable amounts of person time at risk. More VTEs were studied 
in the compared groups in study 3 and 4 leading to generally better precision of esti-
mates of the IR in these studies. 
Effect measures
The absolute measures of outcome described above indicates whether and to which 
extent the association with the studied exposure is present but does not take confoun-
ding into account. Measures of the strength of the association (i.e. effect size) can be 
calculated in several ways. We used incidence rate differences in studies 1 and 3, which 
describes the strength of the association on the additive scale, however this method is 
also unable to control for confounding. As described above, an association can arise 
both because of a true relationship between the exposure and outcome but also due to 
confounding. The strength of an association is therefore a function of the relative pre-
valence of the causes, both the studied exposure and confounders, which result in the 
outcome. Estimates of the effect can be obtained from regression models accounting 
for known confounders. We used Cox proportional hazards models in studies 1 and 4. 
In study 1, we controlled for age and sex, and in study 4, we were also able to include 
time-varying covariates. In study 3, we considered calculating sub-distributional ha-
zard ratios using the Fine-Gray regression model. 269  This model takes into account 
the competing risks, but the estimate is hard to interpret in a clinically meaningful way 
as it gives information about the instantaneous risk of the studied event among those 
who did not yet have the event, but also among those who experienced the competing 
event(s).270,271 Hence, the Fine-Gray model violates the second principle. Furthermore, 
it is recommended to use the Fine- Gray model in studies of prediction while in etiolo-
gical studies the reporting of rates are recommended.270-272 We therefore used Poisson 
regression for assessment of effects in study 3.
A measure of the absolute risk difference or risk ratio with associated confidence inter-
vals would be a preferable way to report clinically meaningful effects. This is possible 
both for estimates of survival as well as for events with competing risk by use of the 
pseudo values approach where transformation of the cumulative incidences/Kaplan-
Meier estimates enables regression.273 However, the pseudo value method requires a 
certain amount of events and was therefore not applicable in our studies.274
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DISCUSSION OF THE MAIN RESULTS 
STUDY 1: IMPACT OF INITIAL CANCER STAGE ON THE 
INCIDENCE OF VTE
The results from study 1 should be interpreted bearing the limited precision and pow-
er in mind, however the study does contribute to a more detailed understanding of the 
impact of cancer stage on the risk of VTE compared with studies combining all cancer 
types. 24,129,190 The effect of regional spread and distant metastasis did vary considerably 
according to cancer type indicating that cancer stage does not contribute with equal 
proportions to the sufficient cause of VTE in all cancer types. Given the very different 
biology and phenotypes of the ten investigated cancer types, it does seem biologically 
plausible that the effect of cancer stage could vary. The observations from study 1 are 
furthermore consistent with results from the studies of single types of cancer listed in 
Table 2. These estimates are however not directly comparable due to different classi-
fications of cancer stage, study designs and populations, unlike the estimated effects 
of cancer stage on the risk of VTE in different cancer types in study 1.244
STUDY 2: EPIDEMIOLOGY OF VTE IN HEMATOLOGICAL 
CANCERS
The small groups and limited number of events led to imprecise estimates in study 
2, however no studies previously compared the risk of VTE in distinct hematological 
cancer types to the background population. Study 2, therefore, for the first time, gives 
an opportunity to assess the association with VTE in distinct types of hematological 
caner. This gives a more detailed understanding of the epidemiology of VTE for each 
type of the hematological cancers. With the exception of indolent lymphomas, patients 
with both acute and chronic hematological cancers had markedly higher incidence 
rates of VTE compared with the reference subjects within the first year after cancer 
diagnosis. For patients with CLL and myeloma, the IR of VTE was still markedly hig-
her years after the cancer diagnosis, which seems plausible as these cancer types are 
incurable with intermittent disease activity and associated with anticancer treatments 
at these occasions.245   
STUDY 3: LONG-TERM INCIDENCE OF VTE IN CANCER
Estimates were more precise in study 3, however many types of cancer were combined 
in one large group of “other solid tumors”. The possible selection bias in the STAC 
cohort could lead to bias in study 3, because cancer survivors are socially marginali-
zed to a higher degree and have more comorbidities than the non-cancer population.275 
Given that the STAC participants represent the most healthy and socially wealthy part 
of the background population, it is possible that the cancer survivors in the STAC 
cohort are generally better off than cancer survivors in the population, probably resul-
ting in estimates biased towards the null hypothesis. We could have included social 
status, education, and health as confounders to partly correct for this selection bias and 
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increase the external validity of the study.
The observed prolonged increased risk of VTE in some groups of cancer survivors was 
confirmed by a few previous studies, where the five-year cumulative risk of VTE was 
2-5-fold higher compared with the background population.157,160 These studies, how-
ever, included events that occurred within the first few months after the cancer diag-
nosis in these calculations. In order tell cancer survivors whether or not their risk of 
VTE is reduced to that of their healthy friends, only events that occur after successive 
event free survival should be included in the calculations, as exemplified in study 3.246
STUDY 4: VTE IN CHRONIC LYMPHOCYTIC LEUKEMIA
The study population in study 4 was for all practical purposes the total population of 
Danish residents diagnosed with CLL in 2008-2015. Unlike the outcome in studies 
1-3, only 10% of VTEs were objectively confirmed in this study. Furthermore, the 
events included both symptomatic VTE and incidental findings possibly resulting in 
ascertainment bias. This might particularly be the case for CLL patients with second 
primary cancers, as they would tend to undergo more imaging diagnostics than CLL 
patients with no second primary cancer. Nevertheless, the effect of second primary 
cancer on the risk of VTE was considerable, and it is furthermore biologically plausible 
that the observed association is causal.247 The observed increased risk of VTE during 
CLL treatment, in the case of previous VTE and with increasing extent of the disease 
correlates with findings in previous studies.85,132,160-162 
SUMMARY DISCUSSION OF THE FOUR STUDIES
Associations between several cancer specific factors and VTE were investigated in 
the studies in this thesis. Consistent association between cancer type and the risk of 
VTE was observed in studies 1-3. 244-246 In study 1, the risk of VTE did vary by cancer 
stage, but the magnitude of the effect varied dramatically with cancer type. 244 After 
adjustment for cancer type, initial distant metastasis was associated with a higher long- 
term risk of VTE in solid cancers in study 3. Furthermore, the Binet stage of CLL was 
associated with the risk of VTE in study 4. 247 The possibility of confounding must be 
taken into account in the interpretation of the impact of cancer specific factors on the 
risk of VTE. The lack of information about chemotherapy and hospitalizations must be 
taken into account when interpreting the results from study 1-3. Some of the observed 
effect of distant metastasis and regional spread on the risk of VTE may be attributable 
to these confounders, however they are unlikely to explain the entire effect, as other 
studies found considerably higher risk of VTE in advanced stage cancers after adjust-
ment for chemotheraphy.86,153,154,158,160,190 Similarly, the observed prolonged increased 
risk of VTE in hematological cancer patients in study 3 may also be confounded by 
repeated treatments, but disease activity in itself may also contribute. This is also in-
dicated in other studies where the risk of VTE in cancer patients was high even before 
administration of anticancer treatment.27,203 Additionally, we observed higher risk of 
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VTE in subjects with β2-microglobulin levels above 4 mg/L indicating that the activity 
of CLL is associated with the risk of VTE. 247 
The effect of time since cancer diagnosis was a theme in all four studies. The cumu-
lative incidence curves of VTE inclined steeply within the first year after cancer diag-
nosis in study 1, most pronounced for those with distant metastasis. For localized can-
cer types with typically good prognosis (i.e. colorectal, breast and prostate cancer), 
the incidence was however more constant throughout follow-up. 244 This observation 
is in line with the role of disease activity in the etiology of VTE discussed above, and 
also with observations from study 2: The acute, aggressive hematological cancer types 
were associated with high risks of VTE within the first year after the cancer diagnosis 
compared with references unlike the incurable hematological cancer types that were 
associated with higher risk of VTE both in close proximity to the cancer diagnosis 
and after several years. Some of the cancer survivors in study 3 presumably lived with 
incurable/chronic cancer while others were cured. The risk of VTE for (previous) co-
lorectal cancer patients alive five years after the cancer diagnosis was similar to the 
reference population, whereas patients with (probably chronic) hematological cancer 
types had considerably higher long-term risk of VTE than the references. The cumu-
lative incidence of VTE after a CLL diagnosis accordingly increased rather linearly 
throughout follow-up in study 4 if restricted to CLL patients without second primary 
cancers.247 However, second primary cancer was strongly associated with the risk of 
VTE in study 4. The cumulative incidence of second primary cancer increased steeply 
within the first few months after the CLL diagnosis.247 
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CONCLUSION OF THE THESIS
 
The studies included in the thesis were based on data from high quality registers. 
Outcome, i.e. VTE in study 1-3 were objectively confirmed, as was outcome for 10% 
of subjects in study 4. The studies were in general not suitable for significance testing 
but did nonetheless suggest rejection of the four null hypotheses.
Study 1: The effect of distant metastatic and regional spread cancer varied conside-
rably with cancer type. For some cancer types, the risk increased in a “dose-depen-
dent” manner with more extensive cancer, while the risk of VTE was quite high or 
rather low regardless of cancer stage in other cancer types. 244
Study 2: The risk of VTE was higher in aggressive lymphoma, CLL and myeloma pa-
tients compared with references –for the latter two types even several years after the 
diagnosis of hematological cancer.245
Study 3: The IR of VTE was generally higher in cancer survivors compared with re-
ference subjects, highest in the hematological cancers with a 5-fold higher risk of 
VTE even later than five years after the diagnosis of cancer. However, the risk of VTE 
in survivors of some solid cancer types attenuated to levels similar to the reference 
population.246
Study 4: Exposure to second primary cancer after the CLL diagnosis and a history 
of VTE before the CLL diagnosis was associated with a 4-5 - fold higher risk of VTE, 
while the risk of VTE varied less according to CLL prognostic markers. Ignoring the 
competing risk of second primary cancer lead to an overestimation of the cumulative 
incidence of VTE.247
The studies overall indicate that the type, extent and activity of cancer are all part of the 
etiology of cancer-associated VTE, and that the impact of the cancer specific factors 
vary by time since cancer diagnosis and cancer type. It is always important to evalua-
te the risk of VTE with regard to time since cancer diagnosis, however not only in the 
sense that the risk of VTE is uniformly high in the first period after cancer diagnosis. 
For cancer survivors and generally also those with less aggressive types, the long-term 
incidence of VTE may actually be more relevant because it can be markedly higher 
than the background population. Second primary cancers increases the risk of VTE 
considerably and must be taken into account even in studies of cancer-associated VTE 
with short follow-up.
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The presented studies contributes to a more detailed understanding of the epidemio-
logy of cancer-associated VTE. The authors of the ISTH guideline on classification of 
VTE discuss when cancer is no longer a risk factor for VTE. 48 Based on the observa-
tions in the presented studies it should depend on cancer specific factors, though the 
long-term incidence of VTE needs further investigation. Second primary cancers or 
relapses are important competing risks for cancer-associated VTE, probably also in 
studies with shorter follow-up. 
Cancer specific factors play complex roles in the etiology of VTE. This implies that 
future studies in the field of cancer-associated VTE should preferably be very detailed 
regarding cancer specific factors. Furthermore, patient related factors and possible ad-
ditional cancers contributes to the complexity. The interplay between all these causes 
changes by time since cancer diagnosis leaving much etiology of cancer-associated 
VTE yet to be learned. Bearing this in mind, condensing all relevant knowledge into 
one common model for prediction of VTE in cancer patients seems an insuperable task.
In a just published survey concerning cancer patients’ awareness of thrombosis, 72% 
of the 1344 respondents did not know that cancer entailed an increased risk of VTE.276 
This means that the patients represent an unexploited option for early diagnosis and 
treatment of cancer-associated VTE. If we educate cancer patients in signs and symp-
toms  of VTE in the same breath as we teach them about neutropene febrilia, they 
might report these rather than just thinking of the cough, chest pain, leg tenderness or 
dizziness as a part of their cancer journey, as mentioned in the study by Noble et al.3 
Hence, my final remark is an invitation to policy makers, colleagues and patient orga-
nizations to corporate on bringing awareness of VTE into the public.
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APPENDIX 1. ALGORITHMS FOR MAPPING OF CANCER 
STAGE
ALGORITHM 1: ALL NORWEGIAN CANCER STAGES
The algorithm for mapping all Norwegian cancer exposed to the principal classifica-
tion: Cases with stage code”3” is moved to regional spread as the description transla-
ted from Norwegian is” organ metastasis to same part of the body”. Local spread to 
neighbor organs is not per se classified as distant metastasis. The Danish data coded 
in TNM is mapped to the principal classification according to international standards 
and ICBP. We have made this decision in order to harmonize Danish and Norwegian 
in the most precise manner, concerning international terminology.
• localized cancer; stage ==0 (original Norwegian code 0 and 8)
• regional spread, stage ==1 (original Norwegian code A, D, 1, 3, 5, 6 )
• distant metastasis; stage ==2 (original Norwegian code B,C, 2,4,7)
• stage unknown; stage==3 (original Norwegian code 9) 
 
A minor part of Norwegian colorectal – and gynecological cancers could have meta-
stasis codes in the Duke’s respective FIGO systems, this variable is not included in 
the merged cohort. Is this variable available in the Tromsø and HUNT databases be-
fore merging?
Breast cancer does have a TNM –based code in the Norwegian cancer registry – va-
riable name: Stadium. Further more the code Stadium_B excists in the Norwegian 
cancer registry, it is identical to Stadium for all values of Stadium except: “ukjent 
(999)”. In case of “ukjent (999)”the value from the variable “Metastase” is added. 
The “Metastase” code is based on TNM classification from 1986 (https://www.kreftre-
gisteret.no/Registrene/Datautlevering/Opplysninger-i-databasen/Ovrige-variable-i-
Kreftregisterets-insidensregister/ ). For all other solid tumors 40-50% have TNM data 
in the national cancer registry. 
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ALGORITHM 2 (A, B AND C): CANCER STAGES IN DCH 
BEFORE 2004
Supplementary table 1. The variable C_UDBRED values 1, 2, 3 and 4 covers both FIGO and 
Duke’s.
c_udbred v_meaning 
A  Unspecified: By coding                                             
B  Not applied: Not cancer                                          
0 Stadium 0, dysplasia, carcinoma in situ (gyn. tumors)        
1 Stadium I (gyn. tumor)/Dukes A                                   
2 Stadium II (gyn. tumor)/Dukes B                                  
3 Stadium III (gyn. tumor)/Dukes C                                 
4 Stadium IV (gyn. tumor) /Dukes D                                  
5 localized (incl. Pre-ankroses outside uterus and benign tumors) 
6 Regional spread                                               
7 Distant metastaser                                                  
9 Unspecified by coding                                              
 
(http://www.esundhed.dk/dokumentation/Registre/Sider/Register.aspx?rp:A_Register=23&r-
p:Visning=3&)
Algorithm for breast239, prostate80, bladder, kidney, colorectal 239, pancreas, lung239 
and upper gastrointestinal (GI) cancer:
• localized cancer; stage ==0 (original code in C_UDBRED 0, 1, 2 and 5)
• regional spread; stage ==1 (original code in C_UDBRED 3 and 6, 
• distant metastasis; stage ==2 (original code in C_UDBRED 4 and 7)
• stage unknown; stage ==3(original code in C_UDBRED 9, A)
• Exposed with the code ”B” in C_UDBRED are excluded as the translation 
 of this code is: Not applied: Non-cancer.
Algorithm for ovary cancer239
• localized cancer; stage==0 (original code in C_UDBRED 0, 1 and 5)
• regional spread; stage==1 (original code in C_UDBRED 2 and 6)
• distant metastasis; stage==2 (original code in C_UDBRED 3, 4 and 7)
• stage unknown; stage==3(original code in C_UDBRED 9, A)
• Exposed with the code ”B” in C_UDBRED are excluded as the translation 
 of this code is: Not applied: Non-cancer
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Algorithm for uterus and cervix cancer
• localized cancer; stage ==0 (original code in C_UDBRED 0, 1 and 5)
• regional spread; stage ==1 (original code in C_UDBRED 2, 3 og 6)
• distant metastasis; stage ==2 (original code in C_UDBRED 4 og 7)
• stage unknown; stage ==3 (original code in C_UDBRED 9, A)
• Exposed with the code ”B” in C_UDBRED are excluded as the translation 
 of this code is: Not applied: Non-cancer
ALGORITHM 3: CANCER STAGES IN DCH AFTER JANUARY 1ST 
2004
BEFORE RUNNING ALGORITHM 3: SET CANCER STAGE TO UNKNOWN 
==3 BY DEFAULT, map to relevant stages by this algorithm: 
Participants in the DHC diagnosed with cancer from 2004 and forwards have to be 
mapped to the principal classification ”local”, ”regional”, and ”distant metastasis” ba-
sed on the TNM classification. “T” refers to extension/size of primary tumor, “N” re-
fers to lymph node involvement and ”M” to metastasis to other organs. The variable M 
outweigh N and T, and N outweights T. The algorithm therefore is build hierarchically 
and takes M into account before N, which is taken into account before T.
Due to inconsistency between solid tumors on when lymph node affection (N) and 
extent of primary tumor (T) draws the principal label ”regional spread” – and even 
”distant metastasis” we have to work with different versions of algorithm 3. All al-
gorithms are designed according to / adapted from references 6 and 7 when no other 
are mentioned.
The variable ”M”
At first we look into metastasis to other organs (M0 = no metastasis, M1= yes). M0 
has the code AZCD40x, M1 has the code AZCD41x. If ”M” is unknown it is coded 
AZCD49x. This step is equal for all solid tumors.
All with TNM AZCD41x are mapped to stage==2. (i.e. ”replace stage=2”  if a TNM 
code corresponding to AZCD41x exists)
All with TNM AZCD40x are mapped to stage==0; if stage==3
(If TNM code is AZCD49x stage==3 is maintained)
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The variable “N”
Now we look into lymph node involvement in the TNM classification. It is divided 
into four categories: N0, N1, N2 and N3 and unknown. N0 has the code AZCD3.0x. 
N1 has the code AZCD31x. N2 has the code AZCD32x. N3 has the code AZCD33x. 
If unknown lymph node affection, the code is AZCD39x. Not all types of solid tumors 
are classified by all four N-categories. 
For prostate80, pancreas, cervix, ovary239 and kidney cancer:
• All with TMN AZCD32x is mapped to stage==2
• All with TNM AZCD33x is mapped to stage==2
• All with TNM AZCD31x is mapped to stage==1 if not already stage==2
• All with TNM AZCD30x is mapped to stage==0 if stage==3
For lung239 og uterus cancer:
• All with TNM AZCD33x is mapped to stage==2
• All with TMN AZCD32x is mapped to stage==1 if not already stage==2
• All with TNM AZCD31x is mapped to stage==1 if not already stage==2
• All with TNM AZCD30x is mapped to stage==0; if stage==3
For breast239, upper GI, bladder and colorectal cancer239:
• All with TNM AZCD33x is mapped to stage==1 if not already stage==2
• All with TMN AZCD32x is mapped to stage==1 if not already stage ==2
• All with TNM AZCD31x is mapped to stage==1 if not already stage==2
• All with TNM AZCD30x is mapped to stage==0; if stage==3
The variable “T”
At last we look into extension of primary tumor. As for ”N” varying levels of ”T” trig-
gers mapping to ”regional” in different tumors. The AZCD codes for T is the following:
T0: AZCD10x 
Ta:AZCD11x
Tis:AZCD12x
T1:AXCD13x
 T1a: AZCD13A
 T1b: AZCD13B
 T1c: AZCD13C
T2.AZCD14x
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T3:AZCD15x
T4:AZCD16x 
T unknown:AZCD19x 
About T0: we chose to include this as it is an option to have metastatic cancer without 
detected primary tumor. 
Algorithms:
For lung239, pancreas, prostate80, bladder and kidney:
• AZCD10x is mapped to stage==0; if stage==3
• AZCD11x is mapped to stage==0; if stage==3
• AZCD12x is mapped to stage==0; if stage==3
• AXCD13x is mapped to stage==0; if stage==3
• AZCD14x is mapped to stage==0; if stage==3
• AZCD15x is mapped to stage==1; if stage==0 or stage==3
• AZCD16x is mapped to stage==1; if stage==0 or stage==3
• AZCD19x does not give rise to alteration of stage
For upper GI, colorectal239 and breast cancer239:
• AZCD10x is mapped to stage ==0; if stage ==3
• AZCD11x is mapped to stage ==0; if stage ==3
• AZCD12x is mapped to stage ==0; if stage ==3
• AXCD13x is mapped to stage ==0; if stage ==3
• AZCD14x is mapped to stage ==0; if stage ==3
• AZCD15x is mapped to stage ==0; if stage ==3
• AZCD16x is mapped to stage ==1; if stage ==0 or stage==3
• AZCD19x does not give rise to alteration of stage
For uterus and cervix:
• AZCD10x AZCD11x, AZCD12x are excluded as these codes covers 
 carcinoma in situ (CIS), which is not coded as cancer.
• AXCD13x is mapped to stage ==0; if stage==3
• AZCD14x is mapped to stage ==1; if stage ==0 or stage ==3
• AZCD15x is mapped to stage ==1; if stage ==0 or stage ==3
• AZCD16x is mapped to stage ==1; if stage ==0 or stage ==3
• AZCD19x does not give rise to alteration of stage
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For ovary239:
• AZCD10x is mapped to stage ==0; if stage ==3
• AZCD11x is mapped to stage ==0; if stage ==3
• AZCD12x is mapped to stage ==0; if stage ==3
• AZCD131 is mapped to stage ==0; if stage ==3
• AZCD13A is mapped to stage ==0; if stage ==3
• AZCD13B is mapped to stage ==0; if stage ==3
• AZCD13C is mapped to stage ==1; if stage ==0 or stage ==3
• AZCD14x is mapped to stage ==1; if stage ==0 or stage ==3
• AZCD15x is mapped to stage ==2; if stage ==0 or stage ==1 or stage ==3
• AZCD16x is mapped to stage ==2; if stage ==0 or stage ==1 or stage ==3
• AZCD19x does not give rise to alteration of stage
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